Page last updated: 2024-08-21

indazoles and Local Neoplasm Recurrence

indazoles has been researched along with Local Neoplasm Recurrence in 119 studies

Research

Studies (119)

Timeframe	Studies, this research(%)	All Research%
pre-1990	1 (0.84)	18.7374
1990's	2 (1.68)	18.2507
2000's	5 (4.20)	29.6817
2010's	76 (63.87)	24.3611
2020's	35 (29.41)	2.80

Authors

Authors	Studies
Braicu, E; Carbone, V; Cibula, D; Colombo, N; Frenel, JS; Ghizzoni, V; Giolitto, S; Giudice, E; Lorusso, D; Musacchio, L; Perri, MT; Pignata, S; Ricci, C; Salutari, V; Scambia, G; Zagouri, F	1
Choi, MC; Jeong, DH; Kim, BG; Kim, SI; Lee, JK; Lee, JY; Lim, MC; Park, J	1
Harada, H; Iwai, H; Kanda, A; Kawahara, A; Ohe, C; Sawada, S; Sengupta, B; Suzuki, K; Takeda, M; Uemura, Y	1
Agouridis, AP; Mamais, I; Michalinos, A; Pagkali, A	1
Aithal, KB; Albacker, LA; Banka, D; Bolduc, DM; Furman, C; Hao, MH; Irwin, S; Kim, A; Korpal, M; Larsen, N; Montesion, M; Moriarty, AD; Murugesan, K; Nguyen, TV; Prajapati, S; Puyang, X; Rimkunas, V; Sahmoud, T; Vaillancourt, FH; Wick, MJ; Wu, ZJ; Yao, S; Zeng, H; Zhang, X; Zhang, Z; Zheng, GZ; Zhu, P	1
Barquin, A; Churruca, C; Constenla, M; Cueva, JF; de Juan, A; Estévez, P; Fernández, I; Gallego, A; García, Y; González-Martín, A; Guerra, E; Herrero, A; Juárez, A; Legerén, M; Manso, L; Marquina, G; Martín, C; Martín, T; Martínez Bueno, A; Maximiano, C; Palacio, I; Pardo, B; Quindós, M; Sánchez, L; Santaballa, A; Yubero, A	1
Adams, S; Baines, A; Chon, HS; Cloven, NG; Coleman, RL; Dalton, H; Duska, LR; ElNaggar, AC; Gaillard, S; Holloway, RW; Huang, M; Konstantinopoulos, PA; Monk, BJ; Nelsen, LM; O'Cearbhaill, RE; O'Malley, DM; Randall, LM; Samnotra, V; Striha, A; Tarkar, A; Waggoner, S	1
Schorge, JO	1
Anttila, M; Åvall Lundqvist, E; Birrer, MJ; Bjørge, L; dePont Christensen, R; Dimoula, M; Hietanen, S; Krog Vistisen, A; Lindahl, G; Lund, B; Mäenpää, JU; Malander, S; Mirza, MR; Nyvang, GB; Peen, U; Roed, H; Staff, S; Werner, TL; Ør Knudsen, A	1
Banerjee, S; Benigno, B; Bessette, P; Buscema, J; Casado Herraez, A; Gil-Martin, M; Guy, H; Hardy-Bessard, AC; Kalbacher, E; Lau, S; Ledermann, JA; Lindahl, G; Mahner, S; Marmé, F; Matulonis, UA; Mirza, MR; Nøttrup, TJ; Travers, K; Walder, L; Wenham, RM; Woie, K	1
Anakura, M; Ando, K; Darwis, NDM; Hirakawa, T; Hirota, Y; Irie, D; Iwase, A; Kakoti, S; Kaminuma, T; Kumazawa, T; Matsui, T; Murata, K; Nachankar, A; Nakano, T; Noda, SE; Ohno, T; Oike, T; Okonogi, N; Sasaki, Y; Shiba, S; Shibata, A; Tamaki, T; Tokino, T; Yamashita, S	1
Cui, M; Han, L; Wang, L; Wang, Q; Xu, Y	1
Long, X; Zhou, Q; Zou, D	1
Accordi, B; Basso, G; Bresolin, S; Cortese, G; Mariotto, E; Porcù, E; Serafin, V; Veltri, G	1
Walsh, CS	1
Banerjee, S; Clamp, AR; Dive, C; Hall, M; Hasan, J; Jayson, GC; Lyon, AR; Morgan, RD; Orbegoso, C; Rustin, GJS; Taylor, S; Tugwood, J; Zhou, C	1
Albuquerque, EV; Bastos, DA; Bonadio, RC; Cavalcante, A; Coelho, RF; Cordeiro, MD; Nahas, WC; Pontes, J; Sarkis, AS; Sierra, PS	1
Bhatla, N; Khurana, S; Kumar, L; Kumar, S; Malik, PS; Ray, MD; Sharma, A	1
Bhargava, P; Danilov, AV; Dyer, MJS; Fegan, CD; Herbaux, C; Hillmen, P; Huang, X; Humeniuk, R; Jürgensmeier, JM; Karlin, L; Kio, EA; Mitra, SS; Rule, SA; Walter, HS; Yi, PC; Zhou, Z	1
Bhatti, A; Horton, ER; Kerliu, L; Myruski, S; Pervanas, HC; Petrosius, P; Soni, P	1
Bai, J; Kristeleit, R; Monk, BJ; Moore, KN; Tewari, KS; Wolford, JE	1
Casado, J; Chen, YA; Chowdhury, D; D'Andrea, AD; Dezube, BJ; Färkkilä, A; Garcia, E; Graham, JR; Gulhan, DC; Hautaniemi, S; Jacobson, CA; Kochupurakkal, B; Konstantinopoulos, PA; Lako, A; Maliga, Z; Matulonis, UA; Munster, P; Nguyen, H; Park, PJ; Rodig, S; Santagata, S; Schapiro, D; Shapiro, GI; Sorger, PK; Swisher, EM; Yapp, C; Zhou, Y	1
Bajpai, J; Deodhar, K; Ghosh, J; Gulia, S; Gupta, S; Maheshwari, A; Rath, S; Shylasree, TS; Thakur, M	1
Carter, Z; Jewett, BE; Ligon, LA; Miller, MN; Mohammad, I; Ordway, GA	1
Ai, Z; Bao, W; Chen, X; Feng, Y; Gao, W; Huang, H; Jia, H; Jiang, R; Jiang, W; Li, J; Li, Y; Liu, J; Luan, Y; Shi, T; Teng, Y; Wang, X; Wu, S; Yin, S; Yu, A; Zang, R; Zhang, J; Zhang, P; Zhang, W; Zhang, Y; Zhu, J; Zhu, T; Zhu, Y	1
Hattori, Y; Ito, M; Iwata, H; Maeda, O; Mitsuishi, T; Murakami, F; Nagasaka, T; Ogino, H; Uematsu, T	1
Arkenau, HT; Coleman, N; Popat, S; Welsh, L; Yousaf, N	1
Chase, DM; Eakin, CM; Ewongwo, A; Monk, BJ; Pendleton, L	1
Aasen, T; Abdul Moin, NI; Abdul Wafi, S; Aboukameel, A; Abu-Bakar, N; Acharya, A; Ackermans, L; Adaramoye, O; Adarsh, KV; Adeosun, WA; Ahmad, NH; Ahmadi, F; Akanni, O; Akbar, M; Akbulak, RO; Akev, N; Akkaya, Ö; Al-Rashed, S; AlAbbad, S; Alabi, O; Alappat, BJ; Alcalá, S; Alcoutlabi, M; Aleppo, G; Alexander Ross, JB; Alexander, JH; Alexander, R; Alias, A; Alimba, C; Alken, FA; Allan, R; Alpers, M; Alsbou, EM; Amarasiri, SS; An, T; Anastasiadis, F; Anastassiadou, M; Anderson, KC; Andronikos, P; Anheyer, D; Annapurna, K; Anorlu, RI; Anten, MM; Anthopoulos, TD; Araujo-Castillo, RV; Aravamudhan, S; Arawwawala, LDAM; Arulsamy, N; Arunamata, A; Asghar, A; Asiri, AM; Aslanidou, T; Astrakhantseva, IV; Astutik, E; Attanayake, AP; Atwater, BD; Audureau, E; Augusto, S; Bakare, A; Banach, M; Bandelier, P; Banerjee, S; Barral, M; Bascuñán, J; Bates, FS; Bauer, NJC; Bayrak, BB; Beck, RW; Beckervordersantforth, J; Beeri, R; Begum, R; Beldi-Ferchiou, A; Bellingham, G; Ben-Tal, N; Bendib, I; Bergenstal, RM; Berger, MF; Bernasconi, G; Berry, S; Beuvon, F; Bi, WJ; Bi, Z; Bianconi, V; Bibi, I; Blank, BR; Bliemeister, E; Bobkowski, W; Bode, AM; Booth, CM; Bose, U; Boyd, K; Brancato, A; Brenmoehl, J; Brogi, E; Bronzo, P; Brooks, T; Brown, D; Brown, DN; Bruce, D; Buan, MEM; Bueno-Hernández, F; Bugielski, B; Bulavaitė, A; Buscagan, TM; Buxton, R; Caffaro, MM; Cai, Q; Cai, X; Cai, Y; Calhoun, P; Callander, N; Cambier, S; Camparo, P; Canales-Vargas, EJ; Canham, K; Cantu, J; Cao, J; Cao, JW; Cao, P; Cao, T; Cao, X; Caravella, BA; Carcadea, E; Carè, J; Carmichael, P; Carrasco Cabrera, L; Carteaux, G; Carvalho, PDS; Casarez, E; Cazorla, M; Celestrin, CP; Chakraborty, NK; Chan, B; Chandarlapaty, S; Chandgude, AL; Chang, CC; Chang, JH; Chang, X; Chang, Y; Chankhanittha, T; Chantanis, S; Chapovetsky, A; Chavan, S; Chen, B; Chen, D; Chen, F; Chen, G; Chen, H; Chen, J; Chen, K; Chen, KJ; Chen, KP; Chen, L; Chen, MA; Chen, Q; Chen, S; Chen, W; Chen, WF; Chen, X; Chen, Y; Cheng, D; Cheng, J; Cheng, Q; Cheon, GJ; Chiu, SC; Cho, CH; Cho, J; Choi, H; Choi, JS; Choi, YH; Christie, P; Chu, CH; Chu, Y; Chung, DH; Chung, F; Cline, JP; Cohen, A; Cohen, AD; Cohen, NJ; Comen, E; Compter, I; Cong, J; Cong, Z; Cooper, A; Cornud, F; Costa, C; Costa, S; Covey, A; Cowan, AM; Cramer, H; Cruz-Rivera, C; Cui, J; Cui, M; Cui, Y; Cui, YH; Culquichicón, C; Cushman, T; D'Auria, SJ; da Silva, J; Dalgediene, I; Danenberg, HD; Das, S; Dasgupta, K; Daubit, IM; de Oliveira, PD; de Prost, N; De Ruysscher, D; Dearman, K; Decato, D; Delfau-Larue, MH; Deng, L; Dhakate, SR; Dharuman, V; Di Costanzo, N; Dickler, MN; Dinehart, EE; Ding, D; Dinh, TK; Divya, KP; Djifack Tadongfack, T; Do, T; Domínguez-Roldan, R; Domínguez-Zambrano, E; Dömling, A; Donato, MD; Dong, JH; Dong, W; Dong, X; Dong, XR; Dong, Y; Dong, Z; Downs, M; Drutskaya, MS; Du, B; Du, F; Du, H; Du, L; Du, X; Duan, Z; Duangthip, D; Dunstand-Guzmán, E; Duong, F; Eckert, DJ; Edelhäuser, BAH; Eekers, DBP; Efendi, F; Efraimidis, P; Ehrenberg, H; Ehsanbakhsh, Z; Eickholt, C; Eksterowicz, J; El Mobadder, M; El-Araby, IE; El-Magd, MA; El-Tarabany, MS; Elgorban, AM; Engelmann, D; English, KL; Esfandiari, H; Eslami, B; Espinosa-Cuevas, A; Eswara, S; Faber, E; Fan, XH; Fan, Y; Fang, J; Fang, Z; Fantin, VR; Fei, P; Feng, G; Feng, H; Feng, J; Feng, X; Feng, XJ; Fennell, TR; Fernández-Moreira, V; Ferraz, ABF; Ferreras, KN; Flores, K; Flores-Pérez, I; Flox, C; Fluharty, FL; Fokouong Tchoffo, E; Folefack, GO; Foroutan, T; Fort, D; Fourati, S; Fousas, S; Frapard, T; Freguia, S; Friedman, DJ; Friedman, LS; Fu, D; Fu, Q; Fu, Y; Fujinami, S; Furihata, K; Gal, RL; Gan, H; Gao, C; Gao, F; Gao, R; Gao, SS; Gao, W; Gao, XC; Gao, Y; Gao, Z; Garozi, L; Ge, J; Georgiopoulos, A; Gerakiou, K; Ghazimirsaeed, SM; Ghazimirsaeed, ST; Gimeno, MC; Gjestad, R; Glurich, I; Goetchius, E; Goland, S; Goldstein, S; Gonçalves, CM; Gonçalves, H; Gong, Q; Gonzalez, D; Goplen, FK; Gorshkova, EN; Gotsman, I; Govindasamy, V; Granger, CB; Greco, L; Grigoriadou-Skouta, E; Grigoropoulos, P; Grivicich, I; Gromov, NV; Gruber, S; Grytczuk, M; Grzech-Leśniak, K; Gu, L; Gu, S; Gu, Z; Guadagnini, D; Guan, H; Guilliams, M; Guo, J; Guo, L; Gupta, A; Gupta, SK; Gurzu, S; Gutleb, AC; Haban, A; Hablitz, JJ; Hadisuyatmana, S; Hahn, S; Haiges, R; Hallal-Calleros, C; Hamed, M; Hammad, N; Hammer, N; Han, C; Hao, Y; Harnett, J; Has, EMM; Hassanpour, K; Hatzopoulos, D; Hawaldar, R; He, X; He, Y; He, YY; He, Z; Heberman, D; Heckl, D; Hegde, H; Henson, MA; Hernández-Velázquez, VM; Herrera, E; Hijazi, Z; Hirayama, K; Hirth, JM; Hoeben, A; Hohnloser, SH; Hong, M; Hood, K; Hoplock, LB; Hopman, WM; Horlbogen, LM; Hossein Rashidi, B; Hou, G; Hou, H; Hou, J; Hou, Y; Hu, J; Hu, W; Hu, X; Hua, W; Huang, G; Huang, H; Huang, J; Huang, T; Huang, W; Huang, Y; Huang, YD; Huang, Z; Hudis, CA; Hue, S; Huo, J; Hussain, M; Hvas, AM; Ichii, T; Ide Zeuna, J; Ilyas, S; Inoue, T; Iranzo, A; Irfan, M; Iwasa, Y; Iwashita, Y; Izgorodina, EI; J R, A; Jaber, WA; Jaborek, JR; Jacobus, SJ; Jadeja, SD; Jafarabadi, M; Jalan, D; Jamil, MI; Jarrah, S; Jarvis, D; Jayatilaka, KAPW; Jemal-Turki, A; Jeon, YK; Jeong, N; Jeong, SH; Jeong, SY; Jermy, M; Jhaveri, K; Ji, H; Ji, K; Ji, RY; Jiang, F; Jiang, J; Jiang, X; Jiang, Y; Jiao, Q; Jilani, K; Jiménez-Guerrero, P; Jin, L; Jo, YH; Johnson, JG; Johnson, ML; Jones, WS; Jose, S; Jularic, M; Jung, I; Jung, YJ; Jungen, C; Junttila, MR; Kache, S; Kahanovitch, U; Kalantzi, KI; Kallio, T; Kamnoedboon, P; Kang, CH; Kang, H; Kang, J; Kang, KW; Kapoor, P; Karmakar, D; Kartalis, A; Kauranen, P; Kazocina, A; Keikha, F; Keltai, M; Kershaw, SV; Kettani, M; Khalvati, S; Khandhar, S; Khosla, N; Kiely, CJ; Kim, CC; Kim, H; Kim, MJ; Kim, Y; Kim, YH; Kim, YT; Kimoto, E; Kiyu, A; Klatt, N; Kobayashi, M; Koh, J; Köhler, R; Kondadasula, SV; Kong, H; Kong, W; Kong, X; Kotidis, A; Kotwal, A; Kouvari, M; Kozhinov, AN; Kruger, D; Kuang, S; Kuang, Y; Kubota, M; Kuklik, P; Kumar, P; Kumar, SK; Kuo, YF; Kurup, SP; Kusuhara, H; Kuswanto, H; Lacouture, ME; Lambin, P; Lang, CC; Langroudi, FH; Lanman, RB; Larsen, OH; Laskin, J; Le, VH; Leach, M; Lee, BG; Lee, DF; Lee, DS; Lee, HJ; Lee, SB; Lee, YA; Lei, Y; Lekashvili, O; Lelj, F; Lemin, AS; Lemoine, J; Leuschner, R; Li, B; Li, BT; Li, C; Li, D; Li, F; Li, G; Li, H; Li, HW; Li, J; Li, M; Li, P; Li, Q; Li, S; Li, W; Li, X; Li, XY; Li, Y; Li, Z; Lian, Y; Liang, C; Liao, J; Liao, W; Liao, Y; Lin, D; Lin, W; Lin, YL; Lindbäck, J; Lindsay, AP; Ling, J; Linser, PJ; Liu, C; Liu, H; Liu, JJ; Liu, L; Liu, Q; Liu, SF; Liu, X; Liu, Y; Liu, Z; Liu, ZM; Lo Sterzo, C; Lo, ECM; Lobchuk, MM; Lodge, TP; Logotheti, S; Lonial, S; Lopes, G; Lopes, RD; Lopez, J; Lopez, SA; López-Santos, AL; López-Sendón, JL; Loring, Z; Louis, C; Lovita, AND; Lu, DZ; Lu, H; Lu, J; Lu, K; Lu, TT; Lu, Y; Luengo, A; Lum, LG; Luna, JM; Luo, L; Luo, R; Luo, T; Luo, X; Luo, Z; Lv, B; Lymperopoulos, N; Lyras, A; Lyu, Y; M Kannan, A; Ma, H; Ma, M; Ma, Q; Ma, S; Ma, WY; Ma, Y; Maalouf, E; Machado, FA; Maeda, K; Magrans, JO; Maharani, A; Maia, G; Mainwaring, RD; Maji, TK; Majumdar, K; Mannarino, MR; Mansuri, MS; Marinescu, SC; Markatos, G; Marquardt, S; Marraiki, N; Martens, C; Martínez, TJ; Marumo, K; Maruyama, H; Marwani, HM; Marzo, I; Masrati, G; Matamba, P; Mathialagan, S; Matys, J; Mayatra, JM; Mboua, PC; McArthur, T; McCrimmon, RJ; McIntosh, S; McSpadden, S; Medina-Campos, ON; Medvedovsky, AT; Mei, Z; Mekontso-Dessap, A; Menezes, AMB; Meng, J; Meng, P; Meng, Y; Menter, A; Mets, MB; Mets-Halgrimson, R; Metzger, T; Metzler-Nolte, N; Meyer, C; Mi, Y; Michailoviene, V; Mikrogeorgiou, A; Militz, H; Miller Iii, TF; Minarowska, A; Mir, S; Miron, I; Miyake, T; Moayer, F; Modi, S; Moeller, SJ; Mohamad, MN; Mohammed, EHM; Mokhonov, VV; Mondal, A; Moore, J; Moravcova, M; Mordi, IR; Mordi, NA; Mortensen, NP; Moscariello, C; Moser, J; Moynahan, ME; Mu, J; Mu, W; Mudduwa, LKB; Mukherjee, S; Mukhtar, A; Mulkey, DK; Murr, N; Mushtaq, Z; Muthuswamy, N; Mutlu, O; Muto, C; Myroforou, I; Na, KJ; Nabi, M; Nagornov, KO; Nagy, RJ; Naik, A; Nakajima, K; Nam, KT; Nam, YW; Namburath, M; Nammour, S; Namour, A; Namour, M; Nanan, S; Natsume, H; Nave, S; Naveed, A; Nazir, H; Ndubaku, C; Nedospasov, SA; Neradilek, MB; Newcomb, C; Nguépy Keubo, FR; Nguyen, M; Ning, J; Ning, Q; Noguchi, S; Nordahl, SHG; Nordfalk, KF; Norton, L; Noupoue, EM; Nouri, SS; Nowak, JK; Núñez, K; Oakes, K; Odegaard, JI; Ogorodnikova, OL; Ogunsuyi, O; Oh, HK; Oh, HR; Oh, KH; Ohgi, K; Okunade, KS; Oliveira, AG; Olorunfemi, G; Olsen, ML; Olson, BA; Omari, KW; Ondruschka, B; Orfali, R; Orkopoulos, A; Orlowski, RZ; Oser, SM; Oser, TK; Özcan, M; Padilla, V; Paeng, JC; Pajuelo-Lozano, N; Pal, SK; Palmieri, S; Palomeque, E; Pan, W; Panagiotakos, DB; Pandey, M; Pang, D; Pang, Q; Pangarah, CA; Panny, A; Paparella, A; Papirio, S; Papouskova, K; Parang, K; Park, HJ; Park, IK; Park, S; Parker, TL; Parkhomenko, A; Parmon, VN; Parsons, B; Parsons, J; Patel, PR; Patil, S; Patsourakos, NG; Patterson, KC; Pavlidis, P; Pedernera, M; Pedersen, R; Pedraza-Chaverri, J; Pellegrini, M; Peña-Chora, G; Pereira, EDM; Pereira, MADS; Peretz, A; Perez-Padilla, R; Perlman, GY; Perona, R; Petras, C; Phuntsho, S; Picada, JN; Pinder, TA; Piper, LFJ; Pirozzi, F; Pirro, M; Pleckaityte, M; Ploutz-Snyder, LL; Ploutz-Snyder, R; Pogorzelski, A; Poles, L; Postma, AA; Prager, A; Prakash, J; Punn, R; Pützer, BM; Qi, J; Qi, MC; Qi, Y; Qian, J; Qian, Y; Qiang, L; Qiu, J; Qu, Y; Rabiu, KA; Rahighi, S; Rahman, MM; Rahmani, B; Rajkumar, SV; Ramanathan, R; Raras, TYM; Rashi, Y; Rasool, G; Rathore, MG; Ratnawati, R; Ratola, N; Raucci, U; Ray, SK; Razavi, P; Razazi, K; Razek, S; Razi, SS; Reback, M; Reddy, K; Rees, DC; Reginatto, FH; Reich, H; Reis-Filho, JS; Ren, X; Ren, Y; Renner, G; Rey, G; Reymen, B; Riaz, M; Ricci, A; Richardson, PG; Richter, C; Riga, M; Ritchie, C; Rivoal, S; Roberts, W; Robson, ME; Rocha, GZ; Rodrigues, AD; Rogach, AL; Rojas, A; Rosenberg, A; Rosenberg, E; Rosenheck, RA; Roslan, K; Rothenberger, C; Rouschop, KMA; Rubagumya, F; Ryan, CM; Ryder, JW; Saad, MJA; Sacan, O; Sacchi, A; Sahebkar, A; Saini, A; Sainz, B; Sajo, EA; Sakizadeh, J; Saleh, AA; Salgado Júnior, IB; Salvi, R; Samoylova, YV; Samuni, A; Sanchez, DM; Sanchez-Perez, I; Santos, M; Sarapulova, A; Sardot, T; Saud, N; Sauerbier, P; Scaltriti, M; Schaeffer, B; Schalk, DL; Scherschel, K; Schijven, MP; Schreuder, HWR; Schuhmacher, M; Schultz-Lebahn, A; Schwarzl, J; Scott, JM; Sebayang, SK; Seeger, ZL; Segabinazi Peserico, C; Selenica, P; Serio, A; Seruga, B; Shah, A; Shah, C; Shah, PD; Shahrokh Tehraninezhad, E; Shan, A; Shao, Z; Sharma, AMR; Sharma, RK; Shen, J; Shen, R; Shi, X; Shi, Y; Shi, ZE; Shih, YC; Shimohata, H; Shimpi, N; Shin, SH; Shon, HK; Shuvy, M; Siddique, AB; Siegbahn, A; Sikandar, M; Silvani, Y; Singh, A; Singh, AK; Singh, D; Singh, JS; Singh, KP; Singh, M; Situ, B; Skipper, MT; Skouloudi, M; Sloane, BF; Smyrnioudis, N; Snyder, MA; Söhnchen, C; Solis Condor, R; Solit, DB; Someya, S; Song, H; Song, J; Song, W; Song, Y; Sorokina, KN; Soshi, S; Soyer, P; Spitschak, A; Sreekrishnan, TR; Srinivasan, M; Staruschenko, A; Steel, A; Stefan-van Staden, RI; Stein, AM; Strayer, H; Struthers, AD; Su, H; Su, Q; Su, X; Sudore, RL; Sugimura, H; Sugiyama, Y; Sujuti, H; Sumner, SJ; Sun, B; Sun, D; Sun, H; Sun, J; Sun, JY; Sun, X; Sun, Y; Sun, Z; Sung, YC; Surenaud, M; Sutimantanapi, D; Suwandaratne, NS; Swaroop, S; Sychrova, H; Syed, A; Szczepanik, M; Szederjesi, J; Szodorai, R; Tacy, TA; Tadelle, RM; Takayasu, M; Tammeveski, K; Tan, H; Tan, M; Tang, HX; Tang, S; Tang, X; Tanokura, M; Tao, F; Tao, H; Tarafdari, A; Tarín-Carrasco, P; Tasson Tatang, C; Teixeira, JP; Thakur, A; Theobald, A; Thevenot, P; Thomaidis, K; Tian, J; Tillib, SV; Toma, C; Tomita, M; Tonchev, I; Tong, F; Toy, W; Trypuć, M; Tselepis, AD; Tsetseris, L; Tsikouri, GE; Tsikouris, EI; Tsoplifack, CB; Tsoumani, ME; Tsujimoto, R; Tsybin, YO; Tu, J; Tu, TM; Turco, M; Turkyilmaz, IB; Uddin, MJ; Ung, J; Unsihuay, D; Utsunomiya, T; Vagenende, B; Vaishnav, J; Valdes, C; Validad, MH; Valle, J; van Ginkel, MPH; van Grevenstein, WMU; Vanderpuye, V; Vasan, N; Vasilenko, EA; Vasques, GJ; Vavoulis, P; Verani, A; Veziroglu, E; Viegas, A; Vitali, MG; Vitsas, G; Voccio, JP; Vogiatzidis, C; Volow, A; Volpin, F; Vourvahis, M; Wagner, LI; Walkowiak, J; Wallace, R; Wallentin, L; Wan, D; Wan, L; Wan, T; Wang, C; Wang, F; Wang, FN; Wang, H; Wang, J; Wang, L; Wang, Q; Wang, S; Wang, T; Wang, W; Wang, X; Wang, XW; Wang, Y; Wang, YS; Wang, Z; Ward, J; Ward, L; Waseem, R; Watson, DF; Weber, P; Wehrmeister, FC; Wei, CH; Wei, H; Wei, L; Wei, Q; Wei, Y; Weinstock, RS; Weiss, M; Welborn, M; Wen, L; Wen, LM; Wen, Q; Wen, Z; Wesseling, P; Westerbergh, J; White, K; Wick, MP; Willems, S; Wiyasa, IWA; Wójciak, R; Wolkenhauer, O; Won, HH; Wong, J; Woo, YC; Wood, LS; Wu, CT; Wu, CY; Wu, D; Wu, G; Wu, J; Wu, K; Wu, M; Wu, Q; Wu, T; Wu, W; Wu, X; Wu, XT; Wu, Y; Xi, D; Xi, J; Xiang, W; Xiang, Y; Xiao, M; Xiao, Z; Xie, H; Xie, Q; Xie, S; Xie, X; Xing, M; Xing, YL; Xu, C; Xu, X; Xu, Y; Xu, Z; Xue, F; Xue, XD; Yaglioglu, HG; Yamada, H; Yamashita, M; Yan, W; Yan, Z; Yanardag, R; Yang, D; Yang, H; Yang, K; Yang, QQ; Yang, R; Yang, S; Yang, T; Yang, X; Yang, Y; Yao, H; Yao, Y; Yari, D; Yassin, MT; Ye, C; Ye, J; Ye, Q; Yildiz, EA; Ying, S; Yoon, H; Yu, D; Yu, K; Yu, N; Yu, PL; Yuan, C; Yuan, D; Yuan, LJ; Yuan, Z; Yuen, N; Zagatto, AM; Zakaria, Y; Zalewski, AM; Zamora, S; Zavorotinskaya, T; Zeid, JL; Zeinoun, T; Zeng, C; Zerby, HN; Zhan, X; Zhang, A; Zhang, D; Zhang, E; Zhang, F; Zhang, H; Zhang, J; Zhang, L; Zhang, M; Zhang, P; Zhang, Q; Zhang, QY; Zhang, RG; Zhang, S; Zhang, T; Zhang, X; Zhang, Y; Zhang, YY; Zhao, CK; Zhao, H; Zhao, J; Zhao, K; Zhao, Q; Zhao, S; Zhao, T; Zhao, XQ; Zhao, Y; Zhao, Z; Zheng, J; Zheng, L; Zheng, Y; Zhou, B; Zhou, G; Zhou, L; Zhou, T; Zhou, X; Zhu, C; Zhu, J; Zhu, Y; Zhu, ZQ; Zhuang, T; Zimmermannova, O; Zin, NNINM; Zisimos, K; Zoghebi, KA; Zonder, JA; Zou, C; Zwirner, J	1
Barceló, IB; Benigno, B; Berton-Rigaud, D; Bessette, P; Buscema, J; de Jong, FA; du Bois, A; Dørum, A; Gupta, D; Herráez, AC; Herrstedt, J; Kalbacher, E; Lau, S; Ledermann, JA; Levy, T; Lorusso, D; Mahner, S; Matulonis, UA; Mirza, MR; Rimel, BJ; Vergote, I; Wang, P	1
Aoki, D; Hamanishi, J; Harano, K; Hasegawa, K; Hirasawa, T; Hori, K; Kase, Y; Komiyama, S; Kondo, E; Matsuura, M; Nakai, H; Nakamura, H; Nakamura, T; Okamoto, A; Sakata, J; Soeda, J; Sugiyama, T; Sumino, S; Suri, A; Tabata, T; Takehara, K; Takekuma, M; Yanagida, S; Yokoyama, Y	1
Abulizi, G; An, RF; Chen, LP; Chen, QH; Cui, H; Gao, YN; Hao, M; Hou, JM; Huang, XH; Huang, Y; Kong, BH; Li, GL; Liu, JH; Liu, ZL; Lou, G; Lu, WG; Lu, X; Mirza, MR; Tian, XF; Wang, DB; Wang, J; Wang, K; Wang, L; Wen, H; Wu, LY; Wu, XH; Yan, XJ; Yang, HY; Yang, JX; Yin, RT; Zhang, C; Zhang, Y; Zhou, Q; Zhu, JQ	1
Aimone, P; Choueiri, TK; Chowdhury, S; Doehn, C; Donskov, F; Gross-Goupil, M; Haas, N; Izquierdo, M; Kopyltsov, E; Lee, JL; Lim, HY; McDermott, R; Melichar, B; Michael, A; Motzer, RJ; Reaume, MN; Rini, B; Russo, P; Stenzl, A; Sternberg, CN; Varlamov, S; Wood, L; Zemanova, M; Zhang, H	1
Hamanishi, J; Hasegawa, K; Itamochi, H; Kase, Y; Matsumoto, T; Matsuura, M; Miura, K; Nagao, S; Nakai, H; Sumino, S; Suri, A; Takehara, K; Takeshima, N; Tanaka, N; Tokunaga, H; Ushijima, K; Watari, H; Yokoyama, Y	1
Adachi, J; Araki, M; Friboulet, L; Fujita, N; Katayama, K; Katayama, R; Kukimoto-Niino, M; Kutkowska, J; Ma, B; Maruyama, K; Mizuta, H; Nishio, M; Oh-Hara, T; Okada, K; Okuno, Y; Sagae, Y; Sasakura, Y; Shirouzu, M; Simizu, S; Takagi, S; Takemoto, A; Tamai, K; Watanabe, K; Yanagitani, N	1
Bharathan, R; Chuai, Y; Dai, G; Li, Y; Otter, SJ; Rizzuto, I; Stewart, A; Wang, A; Zhang, X	1
Fujita, M; Kamada, R; Nakanishi, K; Nishikawa, T; Oka, T; Shioyama, W; Yagi, T; Yasui, T	1
Drabick, JJ; Mackley, HB; Spengler, M; Wheelden, M	1
Chauhan, R; Khurana, S; Kumar, L; Kumar, S; Malik, PS; Mathur, S; Sharma, A; Singh, M; Sreenivas, V	1
Best, S; Danilov, AV; Kittai, A; Lam, V; Liu, T; Orand, K; Spurgeon, SE	1
Chan, AL; Lang, HC; Leung, JH; Lo, HF; Wang, SY	1
Barlesi, F; Bennouna, J; Berard, H; Besse, B; Debieuvre, D; Gervais, R; Jacquot, S; Lacas, B; Lena, H; Mazières, J; Milleron, B; Molinier, O; Moreau, L; Morin, F; Moro-Sibilot, D; Petit, L; Pignon, JP; Ribassin-Majed, L; Soria, JC; Souquet, PJ; Zalcman, G	1
Scott, LJ	1
Agelaki, S; Fountzilas, G; Georgoulias, V; Hartabilas, E; Karavassilis, V; Katsaounis, P; Kentepozidis, N; Koinis, F; Kotsakis, A; Messaritakis, I; Peroukidis, S; Samantas, E; Varthalitis, II	1
Dinkic, C; Eichbaum, M; Fricke, HC; Gebauer, G; Grischke, EM; Lenz, F; Marme, F; Rom, J; Schmidt, M; Schneeweiss, A; Sohn, C; Wallwiener, M	1
Figlin, RA; Leibovich, BC; Negrier, S; Stewart, GD	1
Aghajanian, C; Alvarez Secord, A; Carney, ME; Coleman, RL; Gray, HJ; Hanjani, P; Hu, W; Kehoe, SM; Landrum, LM; Lankes, HA; Pearl, ML; Richardson, DL; Sill, MW; Sood, AK; Van Le, L; Zhou, XC	1
Barrett, C; Bologna, A; Buck, M; Calvert, P; Debruyne, P; du Bois, A; Friedlander, M; Herzog, TJ; Hilpert, F; Kim, JW; King, MT; Lee, CK; Lesoin, A; Malander, S; Meier, W; Monk, BJ; Petru, E; Poveda, A; Rau, J; Scambia, G; Shimada, M	1
Agarwal, S; Burris, H; Kansra, V; Moore, K; Patel, MR; Zhang, ZY	1
Bosse, T; Bovée, JVMG; Gelderblom, H; Verschoor, AJ; Warmerdam, FARM	1
Agresta, L; Dasgupta, R; Kim, H; Nagarajan, R; Plemmons, A; Pressey, JG; Sorger, JI; Szabo, S; Turpin, BK	1
Longoria, TC; Tewari, KS	1
Gillard, M; Lee, JM; Lipkowitz, S; Zimmer, AS	1
Amiri-Kordestani, L; Banerjee, A; Beaver, JA; Blumenthal, GM; Charlab, R; Chen, XH; Dave, K; Dinin, J; Eradiri, O; Ghosh, S; Goldberg, KB; Horne, HN; Howie, LJ; Ibrahim, A; Ison, G; Janoria, KG; Kelly, SL; Kluetz, PG; Lee, EY; Li, F; Manheng, W; Palmby, TR; Pazdur, R; Philip, R; Pierce, WF; Pierre, V; Ramamoorthy, A; Song, P; Sridhara, R; Tang, S; Yu, J; Zhang, L	1
Asai, T; Horie, S; Ichiyanagi, O; Kabasawa, T; Kato, T; Nishida, H; Sakurai, T; Tsuchiya, N; Yagi, M	1
Alentorn, A; Apra, C; Kalamarides, M; Mokhtari, K; Sanson, M	1
Berek, JS; Berton-Rigaud, D; Colombo, N; Ellard, S; Ghatage, P; Gonzalez-Martin, A; Guo, W; Hazard, S; Ledermann, J; Lesoin, A; Madry, R; Mahner, S; Matulonis, UA; Mirza, MR; Peen, U; Pineda, M; Redondo, A; Reinthaller, A; Rosengarten, O; Sehouli, J; Vergote, I	1
Ethier, JL; Lheureux, S; Oza, AM	1
Konstantinopoulos, PA; Matulonis, UA	1
Bajpai, P; Gupta, VG; Rangaraju, RR; Saha, R	1
Benedetti Panici, P; Tomao, F; Tomao, S	1
Coleman, RL; Richardson, DL; Sill, MW	1
Agarwal, S; Banerjee, S; Benigno, B; Berek, JS; Berton-Rigaud, D; Buscema, J; D'Hondt, V; Del Campo, JM; Hilpert, F; Hudgens, S; Lund, B; Malander, S; Matulonis, UA; Mirza, MR; Oza, AM; Provencher, D; Scambia, G; Sehouli, J; Tinker, AV; Vázquez, IP	1
Aoki, D; Chiyoda, T	1
Abate, ME; Boye, K; Cesari, M; Donati, D; Hompland, I; Longhi, A; Paioli, A; Palmerini, E; Setola, E; Spinnato, P	1
Al-Kawaz, A; Ali, R; Band, V; Green, AR; Madhusudan, S; Mesquita, KA; Miligy, IM; Mirza, S; Rakha, EA; Seedhouse, C; Toss, MS	1
Aravantinos, G; Bamias, A; Dimopoulos, MA; Fountzilas, G; Gavalas, N; Gkerzelis, I; Karavasilis, V; Kostouros, E; Koutras, A; Koutsoukos, K; Samantas, E; Tzannis, K; Zagouri, F	1
Nugent, E; Smith, JA; Tomasino, T; Tran, AT; Zhong, L	1
Wu, L; Zhong, L	1
Akers, LJ; Albritton, KH; Basha, R; Elete, KR; Ray, A	1
Coleman, RL; Kurnit, KC; Westin, SN	1
Bando, M; Endo, S; Hagiwara, K; Kurosaki, A; Mato, N; Niki, T; Onuki, T; Sakamoto, N; Takigami, A; Tetsuka, K; Yamasawa, H	1
Banerjee, S; Bover, I; Dørum, A; Fabbro, M; Follana, P; Goffin, F; Harter, P; Hazard, SJ; Hellman, K; Mahner, S; Matulonis, UA; Mirza, MR; Moore, KN; Pineda, MJ; Provencher, D; Shapira-Frommer, R; Tinker, AV; Tognon, G; Vázquez, IP; Wenham, RM	1
Hasunuma, N; Manabe, M; Osada, SI; Toyoshima, A; Yamada, K; Yamada, M	1
Cohn, DE; Ehrisman, JA; Foote, JR; Havrilesky, LJ; Jewell, E; Liang, MI; Secord, AA	1
Arora, S; Benigno, B; Berek, JS; Canzler, U; Del Campo, JM; Follana, P; Gil-Martin, M; Gilbert, L; Hazard, SJ; Lesoin, A; Lund, B; Mahner, S; Malander, S; Matulonis, UA; Mirza, MR; Monk, BJ; Oza, AM; Provencher, D; Waters, J; Wenham, RM; Woie, K	1
Barangi, M; Bouvet, M; Chawla, SP; Endo, I; Higuchi, T; Hiroshima, Y; Hoffman, RM; Homma, Y; Katsuya, Y; Li, Y; Matsuyama, R; Miyake, K; Murakami, T; Nelson, SD; Oshiro, H; Park, JH; Razmjooei, S; Singh, SR; Sugisawa, N; Zhang, Z	1
Brega, N; Hinson, JM; Houk, BE; Jillela, A; Reddy, N; Voorhees, PM	1
Baird, RD; Carpenter, CL; Chatterjee, M; de Bono, JS; Forster, M; Gevensleben, H; Hylands, L; Iannone, R; Kaye, SB; Kreischer, N; Loughney, J; Miranda, S; Moreno, V; Omlin, A; Riisnaes, R; Sandhu, SK; Schelman, WR; Sun, L; Thway, K; Toniatti, C; Wenham, RM; Wilding, G	1
Burris, HA; Infante, JR	1
Barone, C; Bendell, JC; Bloom, J; Kim, JG; Kim, S; Pastorelli, D; Pericay, C; Ricart, AD; Rosbrook, B; Sobrero, AF; Swieboda-Sadlej, A; Tarazi, J; Tournigand, C; Wainberg, ZA	1
Brady, WE; Campos, SM; DiSilvestro, PA; Hanjani, P; Hensley, ML; Lee, PS; Moxley, KM; O'Cearbhaill, RE; O'Malley, DM; Rose, PG; Rotmensch, J; Thaker, PH; Zuna, RE	1
Broom, RJ; Hadden, P; Jebb, A	1
Minami, T; Nozawa, M; Shimizu, N; Uemura, H; Yamamoto, Y; Yoshimura, K	1
Atzori, F; Basso, U; Bracarda, S; Burattini, L; Buti, S; Cascinu, S; Cerbone, L; Conti, A; De Giorgi, U; De Vivo, R; Derosa, L; Di Lorenzo, G; Falconi, M; Iacovelli, R; Masini, C; Massari, F; Milella, M; Montironi, R; Mosca, A; Muzzonigro, G; Ortega, C; Pagano, M; Paglino, C; Porta, C; Procopio, G; Rizzo, M; Rossi, M; Santini, D; Santoni, M; Sternberg, CN; Verzoni, E	1
Bourlon, MT; Kessler, ER	1
Alcindor, T	1
van der Graaf, WT; van Erp, NP; Vlenterie, M	1
Miura, H; Shirai, H	1
Matsumoto, K; Onda, T; Yaegashi, N	1
Arcangeli, V; Brandes, AA; Cecere, SC; Cinieri, S; Daniele, G; Di Maio, M; Di Napoli, M; Gallo, C; Lorusso, D; Maltese, G; Mosconi, AM; Orditura, M; Panici, PB; Perrone, F; Piccirillo, MC; Pignata, S; Pisano, C; Raspagliesi, F; Ricci, C; Salutari, V; Sambataro, D; Scambia, G; Tamberi, S	1
Abarzúa, Á; Giesen, L; González, S; Molgó, M	1
Chan, JA; Fogelman, DR; Halperin, DM; Hess, KR; Kulke, MH; Malinowski, P; Ng, CS; Phan, AT; Regan, E; Yao, JC	1
Asai, K; Eguchi, Y; Hirata, K; Kawaguchi, T; Kojima, K; Ohsawa, M; Sugitani, A	1
Bokemeyer, C; Oechsle, K; Oing, C; Rink, M; Seidel, C; von Amsberg, G	1
Belile, E; Bradford, C; Carey, T; Chepeha, DB; Dobrosotskaya, I; Eisbruch, A; Malloy, K; McKean, E; McLean, S; Moyer, J; Prince, M; Sacco, AG; Shuman, A; Spector, M; Swiecicki, PL; Wolf, GT; Worden, FP; Zhao, L	1
Dietrich, PY; Haller, S; Koka, A; Leemann, B; Merkler, D; Migliorini, D; Pugliesi-Rinaldi, A; Schaller, K	1
Attenberger, U; Derigs, HG; Dimitrakopoulou-Strauss, A; Egerer, G; Fröhling, S; Gaiser, T; Hohenberger, P; Jakob, J; Kasper, B; Nowak, K; Pilz, LR; Ronellenfitsch, U; Schwarzbach, M	1
Bouttens, F; D'Haene, N; Du Four, S; Duerinck, J; Everaert, H; Le Mercier, M; Michotte, A; Neyns, B; Salmon, I; Van Binst, AM; Vandervorst, F; Verschaeve, V	1
Araki, N; Boku, S; Goto, T; Hiraga, H; Honoki, K; Kawai, A; Matsumine, A; Nakamura, T; Nishida, Y; Sudo, A; Sugiura, H; Ueda, T; Yasuda, T; Yonemoto, T	1
Aerts, JL; Benteyn, D; De Keersmaecker, B; Du Four, S; Duerinck, J; Maenhout, SK; Neyns, B; Thielemans, K	1
Bernhard, JC; Daste, A; François, L; Gross-Goupil, M; Quivy, A; Ravaud, A	1
Abell, F; Apt, D; Chan, S; Fehrenbacher, L; Gendreau, S; Huizing, M; Laing, R; Petrakova, K; Rooney, I; Roylance, R; Singel, S; Vuylsteke, P; Zhou, J	1
Bahlis, N; Baker, KL; Bell, B; Benjamin Suttle, A; Demarini, DJ; Hönemann, D; Pandite, LN; Prince, HM; Rizzieri, DA; Roberts, AW; Spencer, A; Stadtmauer, EA; Tricot, G	1
Blay, JY; Collin, F; De Brauwer, A; Le Cesne, A; Marreaud, S; Pandite, L; Papai, Z; Ray-Coquard, I; Schöffski, P; Scurr, M; Sleijfer, S; van Glabbeke, M; Verweij, J	1
Abrey, LE; Butowski, NA; Chang, SM; Deangelis, LM; Fine, HA; Iwamoto, FM; Lamborn, KR; Mehta, MP; Prados, MD; Robins, HI; Zhang, WT	1
Friedlander, M; Hancock, KC; Hodge, JP; Lager, JJ; Ma, B; Matthys, GM; Messing, MJ; Rischin, D; Stringer, CA	1
Agulnik, M; Chia, S; Clemons, M; Dent, S; Grenci, P; Ivy, P; Leighl, NB; Oza, AM; Pritchard, KI; Taylor, SK; Wang, L	1
Chowbay, B; Gao, F; Goh, BC; Ivy, P; Koh, TS; Leong, SS; Lim, WT; Ng, QS; Singh, O; Tan, DS; Tan, EH; Thng, CH; Toh, CK	1
Bischofs, E; Eichbaum, M; Eickhoff, R; Fehm, T; Fersis, N; Fricke, HC; Gebauer, G; Lenz, F; Mayer, C; Schmidt, M; Schneeweiss, A; Sohn, C; Solomayer, E; Wallwiener, M	1
Fujioka, T; Iwasaki, K; Obara, W	1
Crippa, F; Daidone, MG; De Braud, F; Giannatempo, P; Gianni, AM; Lanocita, R; Mariani, L; Messina, C; Morosi, C; Necchi, A; Nicolai, N; Ortega, C; Pennati, M; Sacco, C; Salvioni, R; Sava, T; Schwartz, LH; Zaffaroni, N	1
Barriuso, J; Curtis, CM; Dar, MM; de Bono, J; Groves, MD; Ma, B; McLendon, RE; Mikkelsen, T; Nabors, L; Raizer, J; Reardon, DA; Rosenfeld, S; Suttle, AB; Wen, PY	1
Andrieu, JM; Banu, E; Carpentier, A; Celerier, D; Delattre, JY; Dutrillaux, B; Fauchon, F; Oudard, S; Poupon, MF	1
Brunetti, I; Conte, PF; Dargenio, F; Fanucchi, A; Gadducci, A; Giannessi, PG; Muttini, MP	1
Angelini, F; Ausili Cefaro, GP; Blengio, F; Cirulli, S; Cognetti, F; Colella, E; Giannarelli, D; Lo Russo, V; Merlano, M; Scasso, F	1
Blessing, JA; Hoffman, MA; Morgan, M	1
Blessing, JA; Hoffman, MA; Nuñez, ER	1
Caputo, A; Carapella, CM; Cattani, F; Ciottoli, GB; Floridi, A; Iandolo, B; Paggi, MG; Raus, L; Riccio, A	1

Reviews

14 review(s) available for indazoles and Local Neoplasm Recurrence

Article	Year
Safety Profile of Niraparib as Maintenance Therapy for Ovarian Cancer: A Systematic Review and Meta-Analysis. Current oncology (Toronto, Ont.), 2022, 01-12, Volume: 29, Issue:1 Topics: Carcinoma, Ovarian Epithelial; Female; Humans; Indazoles; Neoplasm Recurrence, Local; Ovarian Neoplasms; Piperidines	2022
Advances in the Treatment of Ovarian Cancer Using PARP Inhibitors and the Underlying Mechanism of Resistance. Current drug targets, 2020, Volume: 21, Issue:2 Topics: Antineoplastic Agents; Benzimidazoles; BRCA1 Protein; BRCA2 Protein; Carcinoma, Ovarian Epithelial; DNA Repair; Drug Resistance, Neoplasm; Female; Humans; Indazoles; Indoles; Neoplasm Recurrence, Local; Ovarian Neoplasms; Phthalazines; Piperazines; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases	2020
Latest clinical evidence of maintenance therapy in ovarian cancer. Current opinion in obstetrics & gynecology, 2020, Volume: 32, Issue:1 Topics: Angiogenesis Inhibitors; Bevacizumab; Carcinoma, Ovarian Epithelial; Female; Humans; Indazoles; Indoles; Neoplasm Recurrence, Local; Ovarian Neoplasms; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors; Randomized Controlled Trials as Topic	2020
Niraparib for the Treatment of Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer. The Annals of pharmacotherapy, 2020, Volume: 54, Issue:10 Topics: Carcinoma, Ovarian Epithelial; Clinical Trials, Phase III as Topic; Fallopian Tube Neoplasms; Female; Humans; Indazoles; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Peritoneal Neoplasms; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors; Progression-Free Survival	2020
Psychological distress among health care professionals of the three COVID-19 most affected Regions in Cameroon: Prevalence and associated factors. Annales medico-psychologiques, 2021, Volume: 179, Issue:2 Topics: 3' Untranslated Regions; 5'-Nucleotidase; A549 Cells; Accidental Falls; Acetylcholinesterase; Acrylic Resins; Actinobacillus; Acute Disease; Acute Kidney Injury; Adaptor Proteins, Signal Transducing; Adenosine; Adenosine Triphosphate; Administration, Inhalation; Administration, Oral; Adolescent; Adult; Advance Care Planning; Africa, Northern; Age Factors; Aged; Aged, 80 and over; Air Pollutants; Air Pollution; Air Pollution, Indoor; Albendazole; Aluminum Oxide; Anastomosis, Surgical; Ancylostoma; Ancylostomiasis; Androstadienes; Angiogenesis Inhibitors; Angiotensin II; Animals; Anti-Bacterial Agents; Anti-Infective Agents; Antibodies, Bispecific; Antibodies, Viral; Anticoagulants; Antihypertensive Agents; Antinematodal Agents; Antineoplastic Agents; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Antioxidants; Antiporters; Antiviral Agents; Apoptosis; Aptamers, Nucleotide; Aromatase Inhibitors; Asian People; Astrocytes; Atrial Fibrillation; Auditory Threshold; Aurora Kinase B; Australia; Autophagy; Autophagy-Related Protein 5; Autotrophic Processes; Bacillus cereus; Bacillus thuringiensis; Bacterial Proteins; Beclin-1; Belgium; Benzene; Benzene Derivatives; Benzhydryl Compounds; beta Catenin; beta-Arrestin 2; Biliary Tract Diseases; Biofilms; Biofuels; Biomarkers; Biomarkers, Tumor; Biomass; Biomechanical Phenomena; Bioreactors; Biosensing Techniques; Biosynthetic Pathways; Bismuth; Blood Platelets; Bone and Bones; Bone Regeneration; Bortezomib; Botulinum Toxins, Type A; Brain; Brain Injuries; Brain Ischemia; Brain Neoplasms; Breast Neoplasms; Breath Tests; Bronchodilator Agents; Calcium Phosphates; Cannabis; Carbon Dioxide; Carbon Isotopes; Carcinogenesis; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cardiac Resynchronization Therapy; Cardiac Resynchronization Therapy Devices; Cardiomyopathies; Cardiovascular Diseases; Cariostatic Agents; Case Managers; Case-Control Studies; Catalysis; Cation Transport Proteins; CD8-Positive T-Lymphocytes; Cecropia Plant; Cell Adhesion; Cell Count; Cell Differentiation; Cell Division; Cell Line; Cell Line, Tumor; Cell Membrane; Cell Movement; Cell Proliferation; Cell Self Renewal; Cell Survival; Cells, Cultured; Cellular Reprogramming; Cellulose; Charcoal; Chemical and Drug Induced Liver Injury; Chemical Phenomena; Chemokines; Chemoradiotherapy; Chemoreceptor Cells; Child; Child Abuse; Child, Preschool; China; Chlorogenic Acid; Chloroquine; Chromatography, Gas; Chronic Disease; Clinical Competence; Coated Materials, Biocompatible; Cochlea; Cohort Studies; Color; Comorbidity; Computer Simulation; Computer-Aided Design; Contraception; Contraceptive Agents, Female; Contrast Media; COP-Coated Vesicles; Coronavirus Infections; Cost of Illness; Coturnix; COVID-19; Creatinine; Cross-Over Studies; Cross-Sectional Studies; Culex; Curriculum; Cyclic N-Oxides; Cytokines; Cytoplasm; Cytotoxicity, Immunologic; Cytotoxins; Databases, Factual; Deep Learning; Delivery, Obstetric; Denitrification; Dental Caries; Denture, Complete; Dexamethasone; Diabetes Complications; Diabetes Mellitus; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Dielectric Spectroscopy; Diet, High-Fat; Dietary Fiber; Disease Models, Animal; Disease Progression; DNA; DNA Copy Number Variations; DNA, Mitochondrial; Dog Diseases; Dogs; Dopaminergic Neurons; Double-Blind Method; Down-Regulation; Doxorubicin; Drug Carriers; Drug Design; Drug Interactions; Drug Resistance, Bacterial; Drug Resistance, Neoplasm; Drug-Related Side Effects and Adverse Reactions; Drugs, Chinese Herbal; Dry Powder Inhalers; Dust; E2F1 Transcription Factor; Ecosystem; Education, Nursing; Education, Nursing, Baccalaureate; Electric Impedance; Electricity; Electrocardiography; Electrochemical Techniques; Electrochemistry; Electrodes; Electrophoresis, Polyacrylamide Gel; Endoplasmic Reticulum; Endothelial Cells; Environmental Monitoring; Enzyme Inhibitors; Epithelial Cells; Epithelial-Mesenchymal Transition; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Estrogen Receptor Modulators; Europe; Evoked Potentials, Auditory, Brain Stem; Exosomes; Feasibility Studies; Female; Ferricyanides; Ferrocyanides; Fibrinogen; Finite Element Analysis; Fistula; Fluorescent Dyes; Fluorides, Topical; Fluorodeoxyglucose F18; Fluticasone; Follow-Up Studies; Food Contamination; Food Microbiology; Foods, Specialized; Forensic Medicine; Frail Elderly; France; Free Radicals; Fresh Water; Fungi; Fungicides, Industrial; Galactosamine; Gastrointestinal Neoplasms; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Gene Frequency; Genetic Predisposition to Disease; Genotype; Gingival Hemorrhage; Glioblastoma; Glioma; Glomerular Filtration Rate; Glomerulosclerosis, Focal Segmental; Glucose; Glucose Transport Proteins, Facilitative; Glucosides; Glutamine; Glycolysis; Gold; GPI-Linked Proteins; Gram-Negative Bacteria; Gram-Positive Bacteria; Graphite; Haplotypes; HCT116 Cells; Healthy Volunteers; Hearing Loss; Heart Failure; Hedgehog Proteins; HEK293 Cells; HeLa Cells; Hemodynamics; Hemorrhage; Hepatocytes; Hippo Signaling Pathway; Histone Deacetylases; Homeostasis; Hospital Mortality; Hospitalization; Humans; Hydantoins; Hydrazines; Hydrogen Peroxide; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Hydroxylamines; Hypoglycemic Agents; Immunity, Innate; Immunoglobulin G; Immunohistochemistry; Immunologic Factors; Immunomodulation; Immunophenotyping; Immunotherapy; Incidence; Indazoles; Indonesia; Infant; Infant, Newborn; Infarction, Middle Cerebral Artery; Inflammation; Injections, Intramuscular; Insecticides; Insulin-Like Growth Factor I; Insurance, Health; Intention to Treat Analysis; Interleukin-1 Receptor-Associated Kinases; Interleukin-6; Intrauterine Devices; Intrauterine Devices, Copper; Iron; Ischemia; Jordan; Keratinocytes; Kidney; Kidney Diseases; Kir5.1 Channel; Klebsiella Infections; Klebsiella pneumoniae; Lab-On-A-Chip Devices; Laparoscopy; Lasers; Lasers, Semiconductor; Lenalidomide; Leptin; Lethal Dose 50; Levonorgestrel; Limit of Detection; Lipid Metabolism; Lipid Metabolism Disorders; Lipogenesis; Lipopolysaccharides; Liquid Biopsy; Liver; Liver Abscess, Pyogenic; Liver Cirrhosis; Liver Diseases; Liver Neoplasms; Longevity; Lung Neoplasms; Luteolin; Lymph Nodes; Lymphocyte Activation; Macaca fascicularis; Macrophages; Mad2 Proteins; Magnetic Resonance Imaging; Male; Mammary Glands, Human; Manganese; Manganese Compounds; MAP Kinase Signaling System; Materials Testing; Maternal Health Services; MCF-7 Cells; Medicaid; Medicine, Chinese Traditional; Melanoma; Membrane Proteins; Mental Health; Mercury; Metal Nanoparticles; Metals, Heavy; Metformin; Methionine Adenosyltransferase; Mice; Mice, Inbred BALB C; Mice, Inbred C3H; Mice, Inbred C57BL; Mice, Inbred CBA; Mice, Knockout; Mice, Nude; Microalgae; Microbial Sensitivity Tests; Microglia; MicroRNAs; Microscopy, Atomic Force; Microscopy, Electron, Scanning; Middle Aged; Mitochondria; Mitochondrial Proteins; Mitral Valve; Mitral Valve Insufficiency; Models, Anatomic; Molecular Structure; Molybdenum; Monocarboxylic Acid Transporters; Moths; MPTP Poisoning; Multigene Family; Multiparametric Magnetic Resonance Imaging; Multiple Myeloma; Muscle, Skeletal; Mutagens; Mutation; Myeloid Cells; Nanocomposites; Nanofibers; Nanomedicine; Nanoparticles; Nanowires; Neoadjuvant Therapy; Neomycin; Neoplasm Grading; Neoplasm Recurrence, Local; Neoplasms; Neoplastic Stem Cells; Neostriatum; Neovascularization, Pathologic; Netherlands; Neuromuscular Agents; Neurons; NF-E2-Related Factor 2; NF-kappa B; Nickel; Nitrogen Oxides; Non-alcoholic Fatty Liver Disease; Nucleosides; Nucleotidyltransferases; Nutritional Status; Obesity, Morbid; Ofloxacin; Oils, Volatile; Oligopeptides; Oncogene Protein v-akt; Optical Imaging; Organic Cation Transport Proteins; Organophosphonates; Osteoarthritis; Osteoarthritis, Hip; Osteoarthritis, Knee; Osteoblasts; Osteogenesis; Oxidation-Reduction; Oxidative Stress; Oxides; Oxygen Isotopes; Pancreas; Pancreaticoduodenectomy; Pandemics; Particle Size; Particulate Matter; Patient Acceptance of Health Care; Patient Compliance; PC-3 Cells; Peptide Fragments; Peptides; Periodontal Attachment Loss; Periodontal Index; Periodontal Pocket; Periodontitis; Peroxides; Peru; Pest Control, Biological; Phosphatidylinositol 3-Kinase; Phosphatidylinositol 3-Kinases; Phylogeny; Pilot Projects; Piperidines; Plant Bark; Plant Extracts; Plant Leaves; Plasmids; Platelet Function Tests; Pneumonia, Viral; Podocytes; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerase Inhibitors; Polyethylene Terephthalates; Polymers; Polymorphism, Single Nucleotide; Porosity; Portugal; Positron-Emission Tomography; Postoperative Complications; Postural Balance; Potassium Channels, Inwardly Rectifying; Povidone; Powders; Precancerous Conditions; Precision Medicine; Predictive Value of Tests; Pregnancy; Prenatal Care; Prognosis; Promoter Regions, Genetic; Prospective Studies; Prostatectomy; Prostatic Neoplasms; Proteasome Inhibitors; Protective Agents; Protein Binding; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Protein Transport; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins c-akt; Psychiatric Nursing; PTEN Phosphohydrolase; Pulmonary Embolism; Pyrimethamine; Radiopharmaceuticals; Rats; Rats, Sprague-Dawley; Rats, Wistar; Reactive Oxygen Species; Receptor, ErbB-2; Receptor, IGF Type 1; Receptors, Estrogen; Receptors, G-Protein-Coupled; Recombinational DNA Repair; Recovery of Function; Regional Blood Flow; Renal Dialysis; Renin; Renin-Angiotensin System; Reperfusion Injury; Reproducibility of Results; Republic of Korea; Respiratory Distress Syndrome; Retrospective Studies; Rhodamines; Risk Assessment; Risk Factors; RNA, Long Noncoding; RNA, Messenger; Running; Saccharomyces cerevisiae; Saccharomyces cerevisiae Proteins; Salinity; Salmeterol Xinafoate; Sarcoma; Seasons; Shoulder Injuries; Signal Transduction; Silicon Dioxide; Silver; Sirtuin 1; Sirtuins; Skull Fractures; Social Determinants of Health; Sodium; Sodium Fluoride; Sodium Potassium Chloride Symporter Inhibitors; Sodium-Glucose Transporter 2 Inhibitors; Soil; Soil Pollutants; Spain; Spectrophotometry; Spectroscopy, Fourier Transform Infrared; Staphylococcal Protein A; Staphylococcus aureus; Stem Cells; Stereoisomerism; Stomach Neoplasms; Streptomyces; Strontium; Structure-Activity Relationship; Students, Nursing; Substance-Related Disorders; Succinic Acid; Sulfur; Surface Properties; Survival Rate; Survivin; Symporters; T-Lymphocytes; Temozolomide; Tensile Strength; Thiazoles; Thiobacillus; Thiohydantoins; Thiourea; Thrombectomy; Time Factors; Titanium; Tobacco Mosaic Virus; Tobacco Use Disorder; Toll-Like Receptor 4; Toluene; Tomography, X-Ray Computed; TOR Serine-Threonine Kinases; Toxicity Tests, Acute; Toxicity Tests, Subacute; Transcriptional Activation; Treatment Outcome; Troponin I; Tumor Cells, Cultured; Tumor Escape; Tumor Hypoxia; Tumor Microenvironment; Tumor Necrosis Factor Inhibitors; Tumor Necrosis Factor-alpha; Tyrosine; Ubiquitin-Protein Ligases; Ubiquitination; Ultrasonic Waves; United Kingdom; United States; United States Department of Veterans Affairs; Up-Regulation; Urea; Uric Acid; Urinary Bladder Neoplasms; Urinary Bladder, Neurogenic; Urine; Urodynamics; User-Computer Interface; Vemurafenib; Verbenaceae; Veterans; Veterans Health; Viral Load; Virtual Reality; Vitiligo; Water Pollutants, Chemical; Wildfires; Wnt Signaling Pathway; Wound Healing; X-Ray Diffraction; Xenograft Model Antitumor Assays; Xylenes; Young Adult; Zinc; Zinc Oxide; Zinc Sulfate; Zoonoses	2021
Vascular endothelial growth factor (VEGF) targeting therapy for persistent, recurrent, or metastatic cervical cancer. The Cochrane database of systematic reviews, 2021, 03-04, Volume: 3 Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Agents; Bevacizumab; Bias; Brachytherapy; Combined Modality Therapy; Confidence Intervals; Female; Gastric Fistula; Gastrointestinal Hemorrhage; Humans; Hypertension; Indazoles; Intestinal Fistula; Intestinal Perforation; Lapatinib; Middle Aged; Neoplasm Recurrence, Local; Progression-Free Survival; Pyridines; Pyrimidines; Quality of Life; Quinazolines; Randomized Controlled Trials as Topic; Sulfonamides; Thromboembolism; Uterine Cervical Neoplasms; Vascular Endothelial Growth Factor A; Young Adult	2021
Pharmacokinetic drug evaluation of niraparib for the treatment of ovarian cancer. Expert opinion on drug metabolism & toxicology, 2018, Volume: 14, Issue:5 Topics: Animals; Antineoplastic Agents; Carcinoma, Ovarian Epithelial; Fallopian Tube Neoplasms; Female; Humans; Indazoles; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Peritoneal Neoplasms; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors; Quality of Life	2018
Update on PARP Inhibitors in Breast Cancer. Current treatment options in oncology, 2018, 04-11, Volume: 19, Issue:5 Topics: BRCA1 Protein; BRCA2 Protein; Breast Neoplasms; Female; Humans; Indazoles; Indoles; Neoplasm Recurrence, Local; Phthalazines; Piperazines; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; Progression-Free Survival	2018
The role of niraparib for the treatment of ovarian cancer. Future oncology (London, England), 2018, Volume: 14, Issue:25 Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ovarian Epithelial; Female; Genes, BRCA1; Genes, BRCA2; Humans; Indazoles; Mutation; Neoplasm Recurrence, Local; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors	2018
Using PARP Inhibitors in the Treatment of Patients With Ovarian Cancer. Current treatment options in oncology, 2018, 11-15, Volume: 19, Issue:12 Topics: Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; BRCA1 Protein; BRCA2 Protein; Carbazoles; Carcinoma, Ovarian Epithelial; Female; Humans; Indazoles; Indoles; Neoplasm Recurrence, Local; Ovarian Neoplasms; Ovary; Phthalazines; Phthalimides; Piperazines; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors	2018
Pharmacotherapy for recurrent ovarian cancer: current status and future perspectives. Japanese journal of clinical oncology, 2015, Volume: 45, Issue:5 Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Carboplatin; Carcinoma, Ovarian Epithelial; Deoxycytidine; Doxorubicin; Everolimus; Female; Folic Acid; Gemcitabine; Humans; Indazoles; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Nivolumab; Ovarian Neoplasms; Paclitaxel; Phthalazines; Piperazines; Poly(ADP-ribose) Polymerase Inhibitors; Polyethylene Glycols; Pyrimidines; Quinazolines; Recombinant Fusion Proteins; Sirolimus; Sulfonamides; Topotecan; TOR Serine-Threonine Kinases; Vinca Alkaloids	2015
Second Line Chemotherapy for Advanced and Metastatic Urothelial Carcinoma: Vinflunine and Beyond-A Comprehensive Review of the Current Literature. The Journal of urology, 2016, Volume: 195, Issue:2 Topics: Antineoplastic Combined Chemotherapy Protocols; Biological Factors; Carboplatin; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Indazoles; Neoplasm Recurrence, Local; Paclitaxel; Pemetrexed; Pyrimidines; Salvage Therapy; Sulfonamides; Urinary Bladder Neoplasms; Vinblastine	2016
Recurrent multiple CNS hemangioblastomas with VHL disease treated with pazopanib: a case report and literature review. CNS oncology, 2015, Volume: 4, Issue:6 Topics: Adult; Angiogenesis Inhibitors; Brain Neoplasms; Cervical Vertebrae; Female; Follow-Up Studies; Hemangioblastoma; Humans; Indazoles; Magnetic Resonance Imaging; Neoplasm Recurrence, Local; Pyrimidines; Sulfonamides; von Hippel-Lindau Disease	2015
Efficacy of Rechallenge of Metastatic Renal Cell Carcinoma Patient With Sunitinib After Prior Resistance to Axitinib: Case Report and Review of the Literature. Clinical genitourinary cancer, 2016, Volume: 14, Issue:5 Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Axitinib; Carcinoma, Renal Cell; Drug Resistance, Neoplasm; Humans; Imidazoles; Indazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Pyrroles; Sunitinib	2016

Trials

53 trial(s) available for indazoles and Local Neoplasm Recurrence

Article	Year
Randomized phase III trial on niraparib-TSR-042 (dostarlimab) versus physician's choice chemotherapy in recurrent ovarian, fallopian tube, or primary peritoneal cancer patients not candidate for platinum retreatment: NItCHE trial (MITO 33). International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, 2021, Volume: 31, Issue:10 Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Drug Resistance, Neoplasm; Female; Humans; Immune Checkpoint Inhibitors; Indazoles; Neoplasm Recurrence, Local; Ovarian Neoplasms; Peritoneal Neoplasms; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors	2021
A single-arm, phase II study of niraparib and bevacizumab maintenance therapy in platinum-sensitive, recurrent ovarian cancer patients previously treated with a PARP inhibitor: Korean Gynecologic Oncology Group (KGOG 3056)/NIRVANA-R trial. Journal of gynecologic oncology, 2022, Volume: 33, Issue:2 Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Ovarian Epithelial; Female; Humans; Indazoles; Neoplasm Recurrence, Local; Ovarian Neoplasms; Piperidines; Platinum; Poly(ADP-ribose) Polymerase Inhibitors; Republic of Korea	2022
Niraparib and dostarlimab for the treatment of recurrent platinum-resistant ovarian cancer: results of a Phase II study (MOONSTONE/GOG-3032). Gynecologic oncology, 2023, Volume: 178 Topics: Antineoplastic Agents; Carcinoma, Ovarian Epithelial; Female; Humans; Indazoles; Neoplasm Recurrence, Local; Ovarian Neoplasms; Poly(ADP-ribose) Polymerase Inhibitors; Quality of Life	2023
Niraparib plus bevacizumab versus niraparib alone for platinum-sensitive recurrent ovarian cancer (NSGO-AVANOVA2/ENGOT-ov24): a randomised, phase 2, superiority trial. The Lancet. Oncology, 2019, Volume: 20, Issue:10 Topics: Aged; Anemia, Aplastic; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Endometrioid; Disease Progression; Female; Humans; Hypertension; Indazoles; Middle Aged; Neoplasm Grading; Neoplasm Recurrence, Local; Ovarian Neoplasms; Piperidines; Progression-Free Survival; Proteinuria; Thrombocytopenia	2019
Pazopanib and Fosbretabulin in recurrent ovarian cancer (PAZOFOS): A multi-centre, phase 1b and open-label, randomised phase 2 trial. Gynecologic oncology, 2020, Volume: 156, Issue:3 Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ovarian Epithelial; Cardiotoxicity; Dose-Response Relationship, Drug; Female; Humans; Indazoles; Neoplasm Recurrence, Local; Neovascularization, Pathologic; Ovarian Neoplasms; Progression-Free Survival; Pyrimidines; Stilbenes; Sulfonamides; Survival Rate	2020
Phase Ib Study of Tirabrutinib in Combination with Idelalisib or Entospletinib in Previously Treated Chronic Lymphocytic Leukemia. Clinical cancer research : an official journal of the American Association for Cancer Research, 2020, 06-15, Volume: 26, Issue:12 Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Imidazoles; Indazoles; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Prognosis; Purines; Pyrazines; Pyrimidines; Quinazolinones; Salvage Therapy; Tissue Distribution	2020
Immunogenomic profiling determines responses to combined PARP and PD-1 inhibition in ovarian cancer. Nature communications, 2020, 03-19, Volume: 11, Issue:1 Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; B7-H1 Antigen; CD8-Positive T-Lymphocytes; DNA Mutational Analysis; Drug Monitoring; Female; Gene Amplification; Humans; Indazoles; Interferons; Macrophages; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Ovary; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors; Programmed Cell Death 1 Ligand 2 Protein; Programmed Cell Death 1 Receptor; Recombinational DNA Repair; Single-Cell Analysis; Treatment Outcome; Tumor Microenvironment	2020
A phase II trial of cytoreductive surgery combined with niraparib maintenance in platinum-sensitive, secondary recurrent ovarian cancer: SGOG SOC-3 study. Journal of gynecologic oncology, 2020, Volume: 31, Issue:3 Topics: Adolescent; China; Cytoreduction Surgical Procedures; Female; Humans; Indazoles; Neoplasm Recurrence, Local; Ovarian Neoplasms; Piperidines; Positron Emission Tomography Computed Tomography; Quality of Life	2020
Psychological distress among health care professionals of the three COVID-19 most affected Regions in Cameroon: Prevalence and associated factors. Annales medico-psychologiques, 2021, Volume: 179, Issue:2 Topics: 3' Untranslated Regions; 5'-Nucleotidase; A549 Cells; Accidental Falls; Acetylcholinesterase; Acrylic Resins; Actinobacillus; Acute Disease; Acute Kidney Injury; Adaptor Proteins, Signal Transducing; Adenosine; Adenosine Triphosphate; Administration, Inhalation; Administration, Oral; Adolescent; Adult; Advance Care Planning; Africa, Northern; Age Factors; Aged; Aged, 80 and over; Air Pollutants; Air Pollution; Air Pollution, Indoor; Albendazole; Aluminum Oxide; Anastomosis, Surgical; Ancylostoma; Ancylostomiasis; Androstadienes; Angiogenesis Inhibitors; Angiotensin II; Animals; Anti-Bacterial Agents; Anti-Infective Agents; Antibodies, Bispecific; Antibodies, Viral; Anticoagulants; Antihypertensive Agents; Antinematodal Agents; Antineoplastic Agents; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Antioxidants; Antiporters; Antiviral Agents; Apoptosis; Aptamers, Nucleotide; Aromatase Inhibitors; Asian People; Astrocytes; Atrial Fibrillation; Auditory Threshold; Aurora Kinase B; Australia; Autophagy; Autophagy-Related Protein 5; Autotrophic Processes; Bacillus cereus; Bacillus thuringiensis; Bacterial Proteins; Beclin-1; Belgium; Benzene; Benzene Derivatives; Benzhydryl Compounds; beta Catenin; beta-Arrestin 2; Biliary Tract Diseases; Biofilms; Biofuels; Biomarkers; Biomarkers, Tumor; Biomass; Biomechanical Phenomena; Bioreactors; Biosensing Techniques; Biosynthetic Pathways; Bismuth; Blood Platelets; Bone and Bones; Bone Regeneration; Bortezomib; Botulinum Toxins, Type A; Brain; Brain Injuries; Brain Ischemia; Brain Neoplasms; Breast Neoplasms; Breath Tests; Bronchodilator Agents; Calcium Phosphates; Cannabis; Carbon Dioxide; Carbon Isotopes; Carcinogenesis; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cardiac Resynchronization Therapy; Cardiac Resynchronization Therapy Devices; Cardiomyopathies; Cardiovascular Diseases; Cariostatic Agents; Case Managers; Case-Control Studies; Catalysis; Cation Transport Proteins; CD8-Positive T-Lymphocytes; Cecropia Plant; Cell Adhesion; Cell Count; Cell Differentiation; Cell Division; Cell Line; Cell Line, Tumor; Cell Membrane; Cell Movement; Cell Proliferation; Cell Self Renewal; Cell Survival; Cells, Cultured; Cellular Reprogramming; Cellulose; Charcoal; Chemical and Drug Induced Liver Injury; Chemical Phenomena; Chemokines; Chemoradiotherapy; Chemoreceptor Cells; Child; Child Abuse; Child, Preschool; China; Chlorogenic Acid; Chloroquine; Chromatography, Gas; Chronic Disease; Clinical Competence; Coated Materials, Biocompatible; Cochlea; Cohort Studies; Color; Comorbidity; Computer Simulation; Computer-Aided Design; Contraception; Contraceptive Agents, Female; Contrast Media; COP-Coated Vesicles; Coronavirus Infections; Cost of Illness; Coturnix; COVID-19; Creatinine; Cross-Over Studies; Cross-Sectional Studies; Culex; Curriculum; Cyclic N-Oxides; Cytokines; Cytoplasm; Cytotoxicity, Immunologic; Cytotoxins; Databases, Factual; Deep Learning; Delivery, Obstetric; Denitrification; Dental Caries; Denture, Complete; Dexamethasone; Diabetes Complications; Diabetes Mellitus; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Dielectric Spectroscopy; Diet, High-Fat; Dietary Fiber; Disease Models, Animal; Disease Progression; DNA; DNA Copy Number Variations; DNA, Mitochondrial; Dog Diseases; Dogs; Dopaminergic Neurons; Double-Blind Method; Down-Regulation; Doxorubicin; Drug Carriers; Drug Design; Drug Interactions; Drug Resistance, Bacterial; Drug Resistance, Neoplasm; Drug-Related Side Effects and Adverse Reactions; Drugs, Chinese Herbal; Dry Powder Inhalers; Dust; E2F1 Transcription Factor; Ecosystem; Education, Nursing; Education, Nursing, Baccalaureate; Electric Impedance; Electricity; Electrocardiography; Electrochemical Techniques; Electrochemistry; Electrodes; Electrophoresis, Polyacrylamide Gel; Endoplasmic Reticulum; Endothelial Cells; Environmental Monitoring; Enzyme Inhibitors; Epithelial Cells; Epithelial-Mesenchymal Transition; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Estrogen Receptor Modulators; Europe; Evoked Potentials, Auditory, Brain Stem; Exosomes; Feasibility Studies; Female; Ferricyanides; Ferrocyanides; Fibrinogen; Finite Element Analysis; Fistula; Fluorescent Dyes; Fluorides, Topical; Fluorodeoxyglucose F18; Fluticasone; Follow-Up Studies; Food Contamination; Food Microbiology; Foods, Specialized; Forensic Medicine; Frail Elderly; France; Free Radicals; Fresh Water; Fungi; Fungicides, Industrial; Galactosamine; Gastrointestinal Neoplasms; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Gene Frequency; Genetic Predisposition to Disease; Genotype; Gingival Hemorrhage; Glioblastoma; Glioma; Glomerular Filtration Rate; Glomerulosclerosis, Focal Segmental; Glucose; Glucose Transport Proteins, Facilitative; Glucosides; Glutamine; Glycolysis; Gold; GPI-Linked Proteins; Gram-Negative Bacteria; Gram-Positive Bacteria; Graphite; Haplotypes; HCT116 Cells; Healthy Volunteers; Hearing Loss; Heart Failure; Hedgehog Proteins; HEK293 Cells; HeLa Cells; Hemodynamics; Hemorrhage; Hepatocytes; Hippo Signaling Pathway; Histone Deacetylases; Homeostasis; Hospital Mortality; Hospitalization; Humans; Hydantoins; Hydrazines; Hydrogen Peroxide; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Hydroxylamines; Hypoglycemic Agents; Immunity, Innate; Immunoglobulin G; Immunohistochemistry; Immunologic Factors; Immunomodulation; Immunophenotyping; Immunotherapy; Incidence; Indazoles; Indonesia; Infant; Infant, Newborn; Infarction, Middle Cerebral Artery; Inflammation; Injections, Intramuscular; Insecticides; Insulin-Like Growth Factor I; Insurance, Health; Intention to Treat Analysis; Interleukin-1 Receptor-Associated Kinases; Interleukin-6; Intrauterine Devices; Intrauterine Devices, Copper; Iron; Ischemia; Jordan; Keratinocytes; Kidney; Kidney Diseases; Kir5.1 Channel; Klebsiella Infections; Klebsiella pneumoniae; Lab-On-A-Chip Devices; Laparoscopy; Lasers; Lasers, Semiconductor; Lenalidomide; Leptin; Lethal Dose 50; Levonorgestrel; Limit of Detection; Lipid Metabolism; Lipid Metabolism Disorders; Lipogenesis; Lipopolysaccharides; Liquid Biopsy; Liver; Liver Abscess, Pyogenic; Liver Cirrhosis; Liver Diseases; Liver Neoplasms; Longevity; Lung Neoplasms; Luteolin; Lymph Nodes; Lymphocyte Activation; Macaca fascicularis; Macrophages; Mad2 Proteins; Magnetic Resonance Imaging; Male; Mammary Glands, Human; Manganese; Manganese Compounds; MAP Kinase Signaling System; Materials Testing; Maternal Health Services; MCF-7 Cells; Medicaid; Medicine, Chinese Traditional; Melanoma; Membrane Proteins; Mental Health; Mercury; Metal Nanoparticles; Metals, Heavy; Metformin; Methionine Adenosyltransferase; Mice; Mice, Inbred BALB C; Mice, Inbred C3H; Mice, Inbred C57BL; Mice, Inbred CBA; Mice, Knockout; Mice, Nude; Microalgae; Microbial Sensitivity Tests; Microglia; MicroRNAs; Microscopy, Atomic Force; Microscopy, Electron, Scanning; Middle Aged; Mitochondria; Mitochondrial Proteins; Mitral Valve; Mitral Valve Insufficiency; Models, Anatomic; Molecular Structure; Molybdenum; Monocarboxylic Acid Transporters; Moths; MPTP Poisoning; Multigene Family; Multiparametric Magnetic Resonance Imaging; Multiple Myeloma; Muscle, Skeletal; Mutagens; Mutation; Myeloid Cells; Nanocomposites; Nanofibers; Nanomedicine; Nanoparticles; Nanowires; Neoadjuvant Therapy; Neomycin; Neoplasm Grading; Neoplasm Recurrence, Local; Neoplasms; Neoplastic Stem Cells; Neostriatum; Neovascularization, Pathologic; Netherlands; Neuromuscular Agents; Neurons; NF-E2-Related Factor 2; NF-kappa B; Nickel; Nitrogen Oxides; Non-alcoholic Fatty Liver Disease; Nucleosides; Nucleotidyltransferases; Nutritional Status; Obesity, Morbid; Ofloxacin; Oils, Volatile; Oligopeptides; Oncogene Protein v-akt; Optical Imaging; Organic Cation Transport Proteins; Organophosphonates; Osteoarthritis; Osteoarthritis, Hip; Osteoarthritis, Knee; Osteoblasts; Osteogenesis; Oxidation-Reduction; Oxidative Stress; Oxides; Oxygen Isotopes; Pancreas; Pancreaticoduodenectomy; Pandemics; Particle Size; Particulate Matter; Patient Acceptance of Health Care; Patient Compliance; PC-3 Cells; Peptide Fragments; Peptides; Periodontal Attachment Loss; Periodontal Index; Periodontal Pocket; Periodontitis; Peroxides; Peru; Pest Control, Biological; Phosphatidylinositol 3-Kinase; Phosphatidylinositol 3-Kinases; Phylogeny; Pilot Projects; Piperidines; Plant Bark; Plant Extracts; Plant Leaves; Plasmids; Platelet Function Tests; Pneumonia, Viral; Podocytes; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerase Inhibitors; Polyethylene Terephthalates; Polymers; Polymorphism, Single Nucleotide; Porosity; Portugal; Positron-Emission Tomography; Postoperative Complications; Postural Balance; Potassium Channels, Inwardly Rectifying; Povidone; Powders; Precancerous Conditions; Precision Medicine; Predictive Value of Tests; Pregnancy; Prenatal Care; Prognosis; Promoter Regions, Genetic; Prospective Studies; Prostatectomy; Prostatic Neoplasms; Proteasome Inhibitors; Protective Agents; Protein Binding; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Protein Transport; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins c-akt; Psychiatric Nursing; PTEN Phosphohydrolase; Pulmonary Embolism; Pyrimethamine; Radiopharmaceuticals; Rats; Rats, Sprague-Dawley; Rats, Wistar; Reactive Oxygen Species; Receptor, ErbB-2; Receptor, IGF Type 1; Receptors, Estrogen; Receptors, G-Protein-Coupled; Recombinational DNA Repair; Recovery of Function; Regional Blood Flow; Renal Dialysis; Renin; Renin-Angiotensin System; Reperfusion Injury; Reproducibility of Results; Republic of Korea; Respiratory Distress Syndrome; Retrospective Studies; Rhodamines; Risk Assessment; Risk Factors; RNA, Long Noncoding; RNA, Messenger; Running; Saccharomyces cerevisiae; Saccharomyces cerevisiae Proteins; Salinity; Salmeterol Xinafoate; Sarcoma; Seasons; Shoulder Injuries; Signal Transduction; Silicon Dioxide; Silver; Sirtuin 1; Sirtuins; Skull Fractures; Social Determinants of Health; Sodium; Sodium Fluoride; Sodium Potassium Chloride Symporter Inhibitors; Sodium-Glucose Transporter 2 Inhibitors; Soil; Soil Pollutants; Spain; Spectrophotometry; Spectroscopy, Fourier Transform Infrared; Staphylococcal Protein A; Staphylococcus aureus; Stem Cells; Stereoisomerism; Stomach Neoplasms; Streptomyces; Strontium; Structure-Activity Relationship; Students, Nursing; Substance-Related Disorders; Succinic Acid; Sulfur; Surface Properties; Survival Rate; Survivin; Symporters; T-Lymphocytes; Temozolomide; Tensile Strength; Thiazoles; Thiobacillus; Thiohydantoins; Thiourea; Thrombectomy; Time Factors; Titanium; Tobacco Mosaic Virus; Tobacco Use Disorder; Toll-Like Receptor 4; Toluene; Tomography, X-Ray Computed; TOR Serine-Threonine Kinases; Toxicity Tests, Acute; Toxicity Tests, Subacute; Transcriptional Activation; Treatment Outcome; Troponin I; Tumor Cells, Cultured; Tumor Escape; Tumor Hypoxia; Tumor Microenvironment; Tumor Necrosis Factor Inhibitors; Tumor Necrosis Factor-alpha; Tyrosine; Ubiquitin-Protein Ligases; Ubiquitination; Ultrasonic Waves; United Kingdom; United States; United States Department of Veterans Affairs; Up-Regulation; Urea; Uric Acid; Urinary Bladder Neoplasms; Urinary Bladder, Neurogenic; Urine; Urodynamics; User-Computer Interface; Vemurafenib; Verbenaceae; Veterans; Veterans Health; Viral Load; Virtual Reality; Vitiligo; Water Pollutants, Chemical; Wildfires; Wnt Signaling Pathway; Wound Healing; X-Ray Diffraction; Xenograft Model Antitumor Assays; Xylenes; Young Adult; Zinc; Zinc Oxide; Zinc Sulfate; Zoonoses	2021
Long-term safety in patients with recurrent ovarian cancer treated with niraparib versus placebo: Results from the phase III ENGOT-OV16/NOVA trial. Gynecologic oncology, 2020, Volume: 159, Issue:2 Topics: Carcinoma, Ovarian Epithelial; Double-Blind Method; Female; Humans; Indazoles; Maintenance Chemotherapy; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors; Progression-Free Survival	2020
Phase 2 single-arm study on the efficacy and safety of niraparib in Japanese patients with heavily pretreated, homologous recombination-deficient ovarian cancer. Journal of gynecologic oncology, 2021, Volume: 32, Issue:2 Topics: Female; Homologous Recombination; Humans; Indazoles; Japan; Neoplasm Recurrence, Local; Ovarian Neoplasms; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors	2021
Niraparib maintenance therapy in patients with platinum-sensitive recurrent ovarian cancer using an individualized starting dose (NORA): a randomized, double-blind, placebo-controlled phase III trial Annals of oncology : official journal of the European Society for Medical Oncology, 2021, Volume: 32, Issue:4 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; China; Double-Blind Method; Female; Humans; Indazoles; Maintenance Chemotherapy; Neoplasm Recurrence, Local; Ovarian Neoplasms; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors	2021
Adjuvant Pazopanib Versus Placebo After Nephrectomy in Patients With Localized or Locally Advanced Renal Cell Carcinoma: Final Overall Survival Analysis of the Phase 3 PROTECT Trial. European urology, 2021, Volume: 79, Issue:3 Topics: Carcinoma, Renal Cell; Disease-Free Survival; Humans; Indazoles; Kidney Neoplasms; Neoplasm Recurrence, Local; Nephrectomy; Pyrimidines; Sulfonamides	2021
Phase 2 single-arm study on the safety of maintenance niraparib in Japanese patients with platinum-sensitive relapsed ovarian cancer. Journal of gynecologic oncology, 2021, Volume: 32, Issue:2 Topics: Female; Humans; Indazoles; Japan; Maintenance Chemotherapy; Neoplasm Recurrence, Local; Ovarian Neoplasms; Piperidines	2021
Pazopanib based oral metronomic therapy for platinum resistant/refractory epithelial ovarian cancer: A phase II, open label, randomized, controlled trial. Gynecologic oncology, 2021, Volume: 162, Issue:2 Topics: Administration, Metronomic; Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ovarian Epithelial; Cyclophosphamide; Drug Resistance, Neoplasm; Etoposide; Female; Humans; Indazoles; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Progression-Free Survival; Pyrimidines; Quality of Life; Sulfonamides	2021
Proapoptotic and immunomodulatory effects of SYK inhibitor entospletinib in combination with obinutuzumab in patients with chronic lymphocytic leukaemia. British journal of clinical pharmacology, 2022, Volume: 88, Issue:2 Topics: Antibodies, Monoclonal, Humanized; Humans; Indazoles; Leukemia, Lymphocytic, Chronic, B-Cell; Neoplasm Recurrence, Local; Pyrazines; Receptors, Antigen, B-Cell; Syk Kinase	2022
Pazopanib or placebo in completely resected stage I NSCLC patients: results of the phase II IFCT-0703 trial. Annals of oncology : official journal of the European Society for Medical Oncology, 2017, May-01, Volume: 28, Issue:5 Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Indazoles; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Protein Kinase Inhibitors; Pyrimidines; Sulfonamides	2017
Second-line pazopanib in patients with relapsed and refractory small-cell lung cancer: a multicentre phase II study of the Hellenic Oncology Research Group. British journal of cancer, 2017, Jun-27, Volume: 117, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Agents; Carboplatin; Cisplatin; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Humans; Indazoles; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplastic Cells, Circulating; Pyrimidines; Small Cell Lung Carcinoma; Sulfonamides; Treatment Outcome	2017
Pazopanib (GW786034) and cyclophosphamide in patients with platinum-resistant, recurrent, pre-treated ovarian cancer - Results of the PACOVAR-trial. Gynecologic oncology, 2017, Volume: 146, Issue:2 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ovarian Epithelial; Cyclophosphamide; Diarrhea; Disease-Free Survival; Drug Resistance, Neoplasm; Fatigue; Female; Humans; Indazoles; Leukopenia; Liver Function Tests; Maximum Tolerated Dose; Middle Aged; Neoplasm Grading; Neoplasm Recurrence, Local; Neoplasms, Cystic, Mucinous, and Serous; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Platinum Compounds; Pyrimidines; Sulfonamides	2017
Paclitaxel With and Without Pazopanib for Persistent or Recurrent Ovarian Cancer: A Randomized Clinical Trial. JAMA oncology, 2018, Feb-01, Volume: 4, Issue:2 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ovarian Epithelial; Double-Blind Method; Drug Resistance, Neoplasm; Female; Humans; Indazoles; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Placebos; Progression-Free Survival; Proto-Oncogene Mas; Pyrimidines; Sulfonamides; Treatment Outcome	2018
Quality of life in patients with advanced epithelial ovarian cancer (EOC) randomized to maintenance pazopanib or placebo after first-line chemotherapy in the AGO-OVAR 16 trial. Measuring what matters-patient-centered end points in trials of maintenance th Annals of oncology : official journal of the European Society for Medical Oncology, 2018, 03-01, Volume: 29, Issue:3 Topics: Adult; Angiogenesis Inhibitors; Antineoplastic Agents; Carcinoma, Ovarian Epithelial; Double-Blind Method; Female; Humans; Indazoles; Maintenance Chemotherapy; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Patient Reported Outcome Measures; Progression-Free Survival; Pyrimidines; Quality of Life; Sulfonamides; Time-to-Treatment	2018
Pazopanib therapy for desmoid tumors in adolescent and young adult patients. Pediatric blood & cancer, 2018, Volume: 65, Issue:6 Topics: Adolescent; Adult; Angiogenesis Inhibitors; Child; Child, Preschool; Female; Fibromatosis, Aggressive; Follow-Up Studies; Humans; Indazoles; Male; Neoplasm Recurrence, Local; Prognosis; Pyrimidines; Retrospective Studies; Sulfonamides; Young Adult	2018
Safety and dose modification for patients receiving niraparib. Annals of oncology : official journal of the European Society for Medical Oncology, 2018, 08-01, Volume: 29, Issue:8 Topics: Administration, Oral; Adult; Body Weight; Dose-Response Relationship, Drug; Female; Humans; Incidence; Indazoles; Maintenance Chemotherapy; Neoplasm Recurrence, Local; Ovarian Neoplasms; Piperidines; Platelet Count; Poly(ADP-ribose) Polymerase Inhibitors; Progression-Free Survival; Retrospective Studies; Risk Factors; Thrombocytopenia	2018
Quality of life in patients with recurrent ovarian cancer treated with niraparib versus placebo (ENGOT-OV16/NOVA): results from a double-blind, phase 3, randomised controlled trial. The Lancet. Oncology, 2018, Volume: 19, Issue:8 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Ovarian Epithelial; Double-Blind Method; Female; Humans; Indazoles; Maintenance Chemotherapy; Middle Aged; Neoplasm Recurrence, Local; Patient Reported Outcome Measures; Piperidines; Progression-Free Survival; Quality of Life; Surveys and Questionnaires	2018
The combination of bevacizumab/temsirolimus after first-line anti-VEGF therapy in advanced renal-cell carcinoma: a clinical and biomarker study. International journal of clinical oncology, 2019, Volume: 24, Issue:4 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Carcinoma, Renal Cell; Humans; Indazoles; Kidney Neoplasms; Middle Aged; Neoplasm Recurrence, Local; Prospective Studies; Pyrimidines; Sirolimus; Sorafenib; Sulfonamides; Sunitinib; TOR Serine-Threonine Kinases; Vascular Endothelial Growth Factor A	2019
Efficacy and safety of niraparib as maintenance treatment in older patients (≥ 70 years) with recurrent ovarian cancer: Results from the ENGOT-OV16/NOVA trial. Gynecologic oncology, 2019, Volume: 152, Issue:3 Topics: Adult; Aged; Aged, 80 and over; Female; Humans; Indazoles; Maintenance Chemotherapy; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Patient Reported Outcome Measures; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors	2019
Niraparib Maintenance Therapy in Patients With Recurrent Ovarian Cancer After a Partial Response to the Last Platinum-Based Chemotherapy in the ENGOT-OV16/NOVA Trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2019, 11-10, Volume: 37, Issue:32 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Double-Blind Method; Female; Humans; Indazoles; Maintenance Chemotherapy; Middle Aged; Neoplasm Recurrence, Local; Organoplatinum Compounds; Ovarian Neoplasms; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors; Progression-Free Survival	2019
Phase I trial of the HSP90 inhibitor PF-04929113 (SNX5422) in adult patients with recurrent, refractory hematologic malignancies. Clinical lymphoma, myeloma & leukemia, 2013, Volume: 13, Issue:4 Topics: Adult; Aged; Aged, 80 and over; Benzamides; Cohort Studies; Disease Progression; Dose-Response Relationship, Drug; Female; Glycine; Hematologic Neoplasms; HSP90 Heat-Shock Proteins; Humans; Indazoles; Male; Middle Aged; Neoplasm Recurrence, Local; Young Adult	2013
The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial. The Lancet. Oncology, 2013, Volume: 14, Issue:9 Topics: Adult; Aged; BRCA1 Protein; BRCA2 Protein; Cohort Studies; Female; Follow-Up Studies; Heterozygote; Humans; Indazoles; Male; Maximum Tolerated Dose; Middle Aged; Mutation; Neoplasm Recurrence, Local; Neoplasms; Ovarian Neoplasms; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors; Prognosis; Prostatic Neoplasms; Tissue Distribution	2013
Axitinib or bevacizumab plus FOLFIRI or modified FOLFOX-6 after failure of first-line therapy for metastatic colorectal cancer: a randomized phase II study. Clinical colorectal cancer, 2013, Volume: 12, Issue:4 Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Bevacizumab; Camptothecin; Colorectal Neoplasms; Disease-Free Survival; Female; Fluorouracil; Humans; Imidazoles; Indazoles; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Organoplatinum Compounds; Young Adult	2013
A phase II evaluation of pazopanib in the treatment of recurrent or persistent carcinosarcoma of the uterus: a gynecologic oncology group study. Gynecologic oncology, 2014, Volume: 133, Issue:3 Topics: Aged; Angiogenesis Inhibitors; Carcinosarcoma; Disease-Free Survival; Female; Humans; Indazoles; Middle Aged; Mixed Tumor, Mullerian; Neoplasm Recurrence, Local; Pyrimidines; Receptors, Vascular Endothelial Growth Factor; Sulfonamides; Treatment Outcome; Uterine Neoplasms	2014
Pazopanib plus weekly paclitaxel versus weekly paclitaxel alone for platinum-resistant or platinum-refractory advanced ovarian cancer (MITO 11): a randomised, open-label, phase 2 trial. The Lancet. Oncology, 2015, Volume: 16, Issue:5 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Humans; Indazoles; Italy; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Platinum; Pyrimidines; Sulfonamides; Treatment Outcome	2015
Pazopanib and depot octreotide in advanced, well-differentiated neuroendocrine tumours: a multicentre, single-group, phase 2 study. The Lancet. Oncology, 2015, Volume: 16, Issue:6 Topics: Aged; Carcinoid Tumor; Cohort Studies; Disease-Free Survival; Female; Humans; Indazoles; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Neuroendocrine Tumors; Pancreatic Neoplasms; Pyrimidines; Receptors, Vascular Endothelial Growth Factor; Sulfonamides; Treatment Outcome	2015
A phase II study evaluating axitinib in patients with unresectable, recurrent or metastatic head and neck cancer. Investigational new drugs, 2015, Volume: 33, Issue:6 Topics: Adult; Aged; Aged, 80 and over; Axitinib; Carcinoma, Squamous Cell; Female; Head and Neck Neoplasms; Humans; Hypertension; Imidazoles; Indazoles; Male; Middle Aged; Neoplasm Recurrence, Local; Protein Kinase Inhibitors; Survival Rate	2015
Preoperative therapy with pazopanib in high-risk soft tissue sarcoma: a phase II window-of-opportunity study by the German Interdisciplinary Sarcoma Group (GISG-04/NOPASS). BMJ open, 2016, Jan-06, Volume: 6, Issue:1 Topics: Angiogenesis Inhibitors; Chemotherapy, Adjuvant; Disease-Free Survival; Endothelial Progenitor Cells; Germany; Humans; Indazoles; Neoplasm Recurrence, Local; Prognosis; Pyrimidines; Receptors, Vascular Endothelial Growth Factor; Risk; Sarcoma; Sulfonamides	2016
Randomized phase II study of axitinib versus physicians best alternative choice of therapy in patients with recurrent glioblastoma. Journal of neuro-oncology, 2016, Volume: 128, Issue:1 Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Agents, Alkylating; Axitinib; Bevacizumab; Brain Neoplasms; Disease-Free Survival; Female; Fluorodeoxyglucose F18; Glioblastoma; Humans; Imidazoles; Indazoles; Lomustine; Male; Middle Aged; Neoplasm Recurrence, Local; Positron-Emission Tomography; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Radiopharmaceuticals; Steroids; Treatment Outcome; Young Adult	2016
Disease progression in recurrent glioblastoma patients treated with the VEGFR inhibitor axitinib is associated with increased regulatory T cell numbers and T cell exhaustion. Cancer immunology, immunotherapy : CII, 2016, Volume: 65, Issue:6 Topics: Adult; Aged; Angiogenesis Inhibitors; Antigens, CD; Axitinib; Biomarkers; Cell Line, Tumor; Cytokines; Disease Progression; Female; Glioblastoma; Hepatitis A Virus Cellular Receptor 2; Humans; Imidazoles; Immunologic Memory; Immunomodulation; Immunophenotyping; Indazoles; Lymphocyte Activation Gene 3 Protein; Lymphocyte Count; Male; Middle Aged; Neoplasm Recurrence, Local; Phenotype; Programmed Cell Death 1 Receptor; Protein Kinase Inhibitors; Receptors, Vascular Endothelial Growth Factor; T-Lymphocyte Subsets; T-Lymphocytes, Regulatory	2016
Pictilisib PI3Kinase inhibitor (a phosphatidylinositol 3-kinase [PI3K] inhibitor) plus paclitaxel for the treatment of hormone receptor-positive, HER2-negative, locally recurrent, or metastatic breast cancer: interim analysis of the multicentre, placebo-c Annals of oncology : official journal of the European Society for Medical Oncology, 2016, Volume: 27, Issue:11 Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Class I Phosphatidylinositol 3-Kinases; Disease-Free Survival; Female; Humans; Indazoles; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Paclitaxel; Receptor, ErbB-2; Sulfonamides	2016
Vascular endothelial growth factor inhibition is not an effective therapeutic strategy for relapsed or refractory multiple myeloma: a phase 2 study of pazopanib (GW786034). Blood, 2009, May-07, Volume: 113, Issue:19 Topics: Adult; Aged; Drug Resistance, Neoplasm; Female; Humans; Indazoles; Male; Maximum Tolerated Dose; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Prognosis; Pyrimidines; Safety; Salvage Therapy; Sulfonamides; Treatment Outcome; Vascular Endothelial Growth Factor A	2009
Pazopanib, a multikinase angiogenesis inhibitor, in patients with relapsed or refractory advanced soft tissue sarcoma: a phase II study from the European organisation for research and treatment of cancer-soft tissue and bone sarcoma group (EORTC study 620 Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2009, Jul-01, Volume: 27, Issue:19 Topics: Adult; Aged; Angiogenesis Inhibitors; Disease-Free Survival; Female; Humans; Indazoles; Male; Middle Aged; Neoplasm Recurrence, Local; Pyrimidines; Sarcoma; Soft Tissue Neoplasms; Sulfonamides	2009
Phase II trial of pazopanib (GW786034), an oral multi-targeted angiogenesis inhibitor, for adults with recurrent glioblastoma (North American Brain Tumor Consortium Study 06-02). Neuro-oncology, 2010, Volume: 12, Issue:8 Topics: Administration, Oral; Adult; Aged; Angiogenesis Inhibitors; Brain Neoplasms; Disease Progression; Female; Glioblastoma; Humans; Indazoles; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm Recurrence, Local; Neovascularization, Pathologic; Pyrimidines; Sulfonamides; Treatment Outcome	2010
A Phase II, open-label study evaluating pazopanib in patients with recurrent ovarian cancer. Gynecologic oncology, 2010, Volume: 119, Issue:1 Topics: Adult; Aged; Aged, 80 and over; CA-125 Antigen; Disease-Free Survival; Fallopian Tube Neoplasms; Female; Humans; Indazoles; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Peritoneal Neoplasms; Pyrimidines; Sulfonamides; Survival Rate	2010
A phase II study of pazopanib in patients with recurrent or metastatic invasive breast carcinoma: a trial of the Princess Margaret Hospital phase II consortium. The oncologist, 2010, Volume: 15, Issue:8 Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Breast Neoplasms; Disease Progression; ErbB Receptors; Female; Humans; Indazoles; Middle Aged; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasm Recurrence, Local; Platelet-Derived Growth Factor; Pyrimidines; Sulfonamides	2010
A Phase II study of pazopanib in Asian patients with recurrent/metastatic nasopharyngeal carcinoma. Clinical cancer research : an official journal of the American Association for Cancer Research, 2011, Aug-15, Volume: 17, Issue:16 Topics: Adult; Aged; Angiogenesis Inhibitors; Anorexia; Asian People; Carcinoma; Diarrhea; Drug Administration Schedule; Fatigue; Female; Humans; Indazoles; Kaplan-Meier Estimate; Male; Middle Aged; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neovascularization, Pathologic; Pyrimidines; Sulfonamides; Treatment Outcome; Vomiting	2011
The PACOVAR-trial: a phase I/II study of pazopanib (GW786034) and cyclophosphamide in patients with platinum-resistant recurrent, pre-treated ovarian cancer. BMC cancer, 2011, Oct-20, Volume: 11 Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ovarian Epithelial; Cyclophosphamide; Drug Resistance, Neoplasm; Female; Humans; Indazoles; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Platinum; Pyrimidines; Sulfonamides	2011
Pazopanib in advanced and platinum-resistant urothelial cancer: an open-label, single group, phase 2 trial. The Lancet. Oncology, 2012, Volume: 13, Issue:8 Topics: Administration, Oral; Aged; Angiogenesis Inhibitors; Antineoplastic Agents; Cisplatin; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Humans; Indazoles; Italy; Kaplan-Meier Estimate; Linear Models; Male; Middle Aged; Neoplasm Recurrence, Local; Proportional Hazards Models; Pyrimidines; Risk Assessment; Risk Factors; Sulfonamides; Time Factors; Treatment Outcome; Tumor Burden; Urologic Neoplasms; Urothelium	2012
A phase I/II trial of pazopanib in combination with lapatinib in adult patients with relapsed malignant glioma. Clinical cancer research : an official journal of the American Association for Cancer Research, 2013, Feb-15, Volume: 19, Issue:4 Topics: Adult; Angiogenesis Inhibitors; Anticonvulsants; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Disease-Free Survival; Drug Delivery Systems; ErbB Receptors; Glioma; Humans; Indazoles; Lapatinib; Neoplasm Recurrence, Local; Neoplasm Staging; Pyrimidines; Quinazolines; Recurrence; Sulfonamides	2013
Phase II study of lonidamine and diazepam in the treatment of recurrent glioblastoma multiforme. Journal of neuro-oncology, 2003, Volume: 63, Issue:1 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Diazepam; Female; Glioblastoma; Humans; Indazoles; Male; Middle Aged; Neoplasm Recurrence, Local; Prognosis; Survival Rate	2003
Epidoxorubicin and lonidamine in refractory or recurrent epithelial ovarian cancer. European journal of cancer (Oxford, England : 1990), 1994, Volume: 30A, Issue:10 Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Drug Resistance; Epirubicin; Female; Humans; Indazoles; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Salvage Therapy	1994
Randomised phase II study of methotrexate (MTX) versus methotrexate plus lonidamine (MTX + LND) in recurrent and/or metastatic carcinoma of the head and neck. European journal of cancer (Oxford, England : 1990), 1994, Volume: 30A, Issue:7 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Female; Head and Neck Neoplasms; Humans; Indazoles; Male; Methotrexate; Middle Aged; Neoplasm Recurrence, Local	1994
Phase II trial of CI-958 in recurrent platinum-refractory ovarian carcinoma. A Gynecologic Oncology Group Study. Gynecologic oncology, 2000, Volume: 79, Issue:3 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Drug Resistance, Neoplasm; Female; Humans; Indazoles; Middle Aged; Neoplasm Recurrence, Local; Organoplatinum Compounds; Ovarian Neoplasms	2000
A phase II trial of CI-958 in recurrent platinum-sensitive ovarian carcinoma: a Gynecologic Oncology Group study. Gynecologic oncology, 2001, Volume: 81, Issue:3 Topics: Adult; Aged; Antineoplastic Agents; Drug Resistance, Neoplasm; Female; Humans; Indazoles; Middle Aged; Neoplasm Recurrence, Local; Organoplatinum Compounds; Ovarian Neoplasms	2001
The potential role of lonidamine (LND) in the treatment of malignant glioma. Phase II study. Journal of neuro-oncology, 1989, Volume: 7, Issue:1 Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Clinical Trials as Topic; Dose-Response Relationship, Drug; Female; Glioma; Humans; Indazoles; Male; Middle Aged; Neoplasm Recurrence, Local; Pyrazoles	1989

Other Studies

53 other study(ies) available for indazoles and Local Neoplasm Recurrence

Article	Year
Clinicopathological investigation of secretory carcinoma cases including a successful treatment outcome using entrectinib for high-grade transformation: a case report. BMC medical genomics, 2022, 01-06, Volume: 15, Issue:1 Topics: Benzamides; Biomarkers, Tumor; Carcinoma; Humans; Immunohistochemistry; In Situ Hybridization, Fluorescence; Indazoles; Neoplasm Recurrence, Local; Oncogene Proteins, Fusion; Salivary Gland Neoplasms; Treatment Outcome	2022
Covalent ERα Antagonist H3B-6545 Demonstrates Encouraging Preclinical Activity in Therapy-Resistant Breast Cancer. Molecular cancer therapeutics, 2022, 06-01, Volume: 21, Issue:6 Topics: Breast Neoplasms; Clinical Trials as Topic; Estrogen Receptor alpha; Female; Fulvestrant; Humans; Indazoles; Neoplasm Recurrence, Local; Pyridines	2022
Real-world safety and effectiveness of maintenance niraparib for platinum-sensitive recurrent ovarian cancer: A GEICO retrospective observational study within the Spanish expanded-access programme. European journal of cancer (Oxford, England : 1990), 2023, Volume: 182 Topics: Carcinoma, Ovarian Epithelial; Female; Humans; Indazoles; Neoplasm Recurrence, Local; Ovarian Neoplasms; Poly(ADP-ribose) Polymerase Inhibitors	2023
Chemotherapy-free, but not quite free chemotherapy. The Lancet. Oncology, 2019, Volume: 20, Issue:10 Topics: Bevacizumab; Female; Humans; Indazoles; Neoplasm Recurrence, Local; Ovarian Neoplasms; Piperidines; Platinum	2019
Niraparib Maintenance Treatment Improves Time Without Symptoms or Toxicity (TWiST) Versus Routine Surveillance in Recurrent Ovarian Cancer: A TWiST Analysis of the ENGOT-OV16/NOVA Trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2019, 12-01, Volume: 37, Issue:34 Topics: BRCA1 Protein; BRCA2 Protein; Disease Progression; Drug Administration Schedule; Female; Germ-Line Mutation; Humans; Indazoles; Maintenance Chemotherapy; Neoplasm Recurrence, Local; Ovarian Neoplasms; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors; Progression-Free Survival; Randomized Controlled Trials as Topic; Risk Assessment; Risk Factors; Time Factors	2019
FGFR Signaling as a Candidate Therapeutic Target for Cancers Resistant to Carbon Ion Radiotherapy. International journal of molecular sciences, 2019, Sep-14, Volume: 20, Issue:18 Topics: A549 Cells; Carcinoma, Squamous Cell; Female; Gene Ontology; Heavy Ion Radiotherapy; High-Throughput Nucleotide Sequencing; Humans; Indazoles; Middle Aged; Neoplasm Recurrence, Local; Pilot Projects; Receptor, Fibroblast Growth Factor, Type 3; Receptor, Fibroblast Growth Factor, Type 4; Signal Transduction; Uterine Cervical Neoplasms	2019
Chemotherapy-free strategy for platinum-sensitive recurrent ovarian cancer. The Lancet. Oncology, 2019, Volume: 20, Issue:12 Topics: Bevacizumab; Female; Humans; Indazoles; Neoplasm Recurrence, Local; Ovarian Neoplasms; Piperidines; Platinum	2019
SYK Targeting Represents a Potential Therapeutic Option for Relapsed Resistant Pediatric International journal of molecular sciences, 2019, Dec-07, Volume: 20, Issue:24 Topics: Aminopyridines; Cell Proliferation; Child; Core Binding Factor Alpha 2 Subunit; Cyclohexylamines; Drug Resistance, Neoplasm; Humans; Indazoles; Morpholines; Neoplasm Recurrence, Local; Oncogene Proteins, Fusion; Oxazines; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Pyrazines; Pyridines; Pyrimidines; Syk Kinase; Tumor Cells, Cultured	2019
Oncologic Outcomes in Young Adults With Kidney Cancer Treated During the Targeted Therapy Era. Clinical genitourinary cancer, 2020, Volume: 18, Issue:2 Topics: Adolescent; Adult; Age Factors; Carcinoma, Renal Cell; Disease-Free Survival; Female; Follow-Up Studies; Humans; Indazoles; Kaplan-Meier Estimate; Kidney; Kidney Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Molecular Targeted Therapy; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Protein Kinase Inhibitors; Pyrimidines; Retrospective Studies; Risk Factors; Sulfonamides; Sunitinib; Young Adult	2020
Oral metronomic chemotherapy for recurrent & refractory epithelial ovarian cancer: A retrospective analysis. The Indian journal of medical research, 2019, Volume: 150, Issue:6 Topics: Administration, Metronomic; Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ovarian Epithelial; Celecoxib; Cyclophosphamide; Drug Therapy; Etoposide; Female; Humans; Indazoles; India; Middle Aged; Neoplasm Recurrence, Local; Progression-Free Survival; Pyrimidines; Recurrence; Sulfonamides	2019
Cost-effectiveness of niraparib, rucaparib, and olaparib for treatment of platinum-resistant, recurrent ovarian carcinoma. Gynecologic oncology, 2020, Volume: 157, Issue:2 Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Ovarian Epithelial; Cost-Benefit Analysis; Drug Costs; Female; Humans; Indazoles; Indoles; Infusions, Intravenous; Markov Chains; Models, Statistical; Neoplasm Recurrence, Local; Ovarian Neoplasms; Phthalazines; Piperazines; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors; Quality of Life; United States	2020
Pazopanib and Oral Cyclophosphamide in Women With Platinum-Resistant or -Refractory Epithelial Ovarian Cancer. JCO global oncology, 2020, Volume: 6 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ovarian Epithelial; Cyclophosphamide; Female; Humans; Indazoles; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Platinum; Pyrimidines; Retrospective Studies; Sulfonamides	2020
Rapid and temporary improvement of depression and anxiety observed following niraparib administration: a case report. BMC psychiatry, 2020, 04-15, Volume: 20, Issue:1 Topics: Anxiety; Depression; Female; Humans; Indazoles; Middle Aged; Neoplasm Recurrence, Local; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors	2020
Long-term multidisciplinary treatment including proton therapy for a recurrent low-grade endometrial stromal sarcoma and pathologically prominent epithelial differentiation: an autopsy case report. BMC women's health, 2020, 07-25, Volume: 20, Issue:1 Topics: Adult; Autopsy; Drainage; Endometrial Neoplasms; Fatal Outcome; Female; Humans; Indazoles; Liver Neoplasms; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Proton Therapy; Pyrimidines; Sarcoma, Endometrial Stromal; Sepsis; Sulfonamides; Young Adult	2020
Lorlatinib Salvages Central Nervous System-Only Relapse on Entrectinib in ROS1-Positive NSCLC. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2020, Volume: 15, Issue:8 Topics: Aminopyridines; Benzamides; Central Nervous System; Humans; Indazoles; Lactams; Lactams, Macrocyclic; Lung Neoplasms; Neoplasm Recurrence, Local; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Pyrazoles	2020
Real world experience of poly (ADP-ribose) polymerase inhibitor use in a community oncology practice. Gynecologic oncology, 2020, Volume: 159, Issue:1 Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Community Health Centers; Cost-Benefit Analysis; Dose-Response Relationship, Drug; Drug Costs; Female; Follow-Up Studies; Gynecology; Humans; Indazoles; Indoles; Medical Oncology; Medication Therapy Management; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Phthalazines; Piperazines; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors; Randomized Controlled Trials as Topic; Retrospective Studies; Workload	2020
Gilteritinib overcomes lorlatinib resistance in ALK-rearranged cancer. Nature communications, 2021, 02-24, Volume: 12, Issue:1 Topics: Aminopyridines; Aniline Compounds; Animals; Apoptosis; Benzamides; Carbazoles; Cell Line; Cell Survival; Crizotinib; Drug Resistance, Neoplasm; Enzyme Inhibitors; Humans; Immunoblotting; Indazoles; Lactams; Lactams, Macrocyclic; Lung Neoplasms; Mice; Mice, Inbred BALB C; Molecular Dynamics Simulation; Neoplasm Recurrence, Local; Piperidines; Proto-Oncogene Proteins; Pyrazines; Pyrazoles; Receptor Protein-Tyrosine Kinases	2021
Symptomatic Sinus Bradycardia in a Patient with Solitary Fibrous Tumor/Hemangiopericytoma Treated with Pazopanib. Internal medicine (Tokyo, Japan), 2021, Sep-15, Volume: 60, Issue:18 Topics: Bradycardia; Hemangiopericytoma; Humans; Indazoles; Male; Neoplasm Recurrence, Local; Pyrimidines; Solitary Fibrous Tumors; Sulfonamides	2021
Durable Major Response With Pazopanib in Recurrent, Heavily Pretreated Metastatic Esthesioneuroblastoma Harboring a Fumarate Hydratase Mutation. JCO precision oncology, 2021, Volume: 5 Topics: Aged; Esthesioneuroblastoma, Olfactory; Female; Fumarate Hydratase; Humans; Indazoles; Mutation; Nasal Cavity; Neoplasm Recurrence, Local; Nose Neoplasms; Pyrimidines; Remission Induction; Retreatment; Sulfonamides; Time Factors	2021
Cost-effectiveness analysis of olaparib and niraparib as maintenance therapy for women with recurrent platinum-sensitive ovarian cancer. Expert review of pharmacoeconomics & outcomes research, 2022, Volume: 22, Issue:3 Topics: Cost-Benefit Analysis; Female; Humans; Indazoles; Neoplasm Recurrence, Local; Ovarian Neoplasms; Phthalazines; Piperazines; Piperidines	2022
Niraparib: First Global Approval. Drugs, 2017, Volume: 77, Issue:9 Topics: Adult; Carcinoma, Ovarian Epithelial; Double-Blind Method; Drug Approval; Fallopian Tube Neoplasms; Female; Humans; Indazoles; Maintenance Chemotherapy; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Peritoneal Neoplasms; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors; Randomized Controlled Trials as Topic; United States; United States Food and Drug Administration	2017
Adjuvant Pazopanib Does Not PROTECT Against Recurrence of High-Risk, Initially Localized Renal Cell Cancer but Does Provide Novel Insights. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2017, 12-10, Volume: 35, Issue:35 Topics: Carcinoma, Renal Cell; Humans; Indazoles; Kidney Neoplasms; Neoplasm Recurrence, Local; Nephrectomy; Pyrimidines; Sulfonamides	2017
The effect of food on the pharmacokinetics of niraparib, a poly(ADP-ribose) polymerase (PARP) inhibitor, in patients with recurrent ovarian cancer. Cancer chemotherapy and pharmacology, 2018, Volume: 81, Issue:3 Topics: Adult; Aged; Area Under Curve; Dietary Fats; Drug Monitoring; Fasting; Female; Food-Drug Interactions; Humans; Indazoles; Middle Aged; Neoplasm Recurrence, Local; Outcome Assessment, Health Care; Ovarian Neoplasms; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors; Therapeutic Equivalency	2018
A remarkable response to pazopanib, despite recurrent liver toxicity, in a patient with a high grade endometrial stromal sarcoma, a case report. BMC cancer, 2018, 01-22, Volume: 18, Issue:1 Topics: Adult; Chemical and Drug Induced Liver Injury; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Indazoles; Liver; Neoplasm Recurrence, Local; Pyrimidines; Sarcoma, Endometrial Stromal; Sulfonamides	2018
FDA Approval Summary: Niraparib for the Maintenance Treatment of Patients with Recurrent Ovarian Cancer in Response to Platinum-Based Chemotherapy. Clinical cancer research : an official journal of the American Association for Cancer Research, 2018, 09-01, Volume: 24, Issue:17 Topics: Aged; BRCA1 Protein; BRCA2 Protein; Clinical Trials as Topic; Drug Approval; Drug-Related Side Effects and Adverse Reactions; Female; Germ-Line Mutation; Humans; Indazoles; Maintenance Chemotherapy; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Peritoneal Neoplasms; Piperidines; Platinum; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; Progression-Free Survival; Risk Assessment	2018
Pazopanib-induced crystal deposition in intestinal mucosa in a patient with retroperitoneal liposarcoma. International journal of urology : official journal of the Japanese Urological Association, 2018, Volume: 25, Issue:6 Topics: Adult; Antineoplastic Agents; Edema; Endoscopy, Gastrointestinal; Humans; Indazoles; Intestinal Diseases; Intestinal Mucosa; Kidney Neoplasms; Liposarcoma; Male; Neoplasm Recurrence, Local; Pyrimidines; Retroperitoneal Neoplasms; Sulfonamides; Tomography, X-Ray Computed	2018
Pazopanib efficacy in recurrent central nervous system hemangiopericytomas. Journal of neuro-oncology, 2018, Volume: 139, Issue:2 Topics: Adult; Angiogenesis Inhibitors; Central Nervous System Neoplasms; Female; Hemangiopericytoma; Humans; Indazoles; Male; Middle Aged; Neoplasm Recurrence, Local; Pyrimidines; Solitary Fibrous Tumors; Sulfonamides; Treatment Outcome	2018
PARP Inhibitors in Ovarian Cancer: A Trailblazing and Transformative Journey. Clinical cancer research : an official journal of the American Association for Cancer Research, 2018, 09-01, Volume: 24, Issue:17 Topics: Female; Humans; Indazoles; Neoplasm Recurrence, Local; Ovarian Neoplasms; Piperidines; Platinum; Poly(ADP-ribose) Polymerase Inhibitors	2018
Pazopanib Monotherapy Is Active in Relapsed and Refractory Metastatic Gastroesophageal Adenocarcinoma and Can Produce Durable Response. Journal of gastrointestinal cancer, 2019, Volume: 50, Issue:4 Topics: Adenocarcinoma; Administration, Oral; Adult; Aged, 80 and over; Drug Resistance, Neoplasm; Esophageal Neoplasms; Esophagus; Fatal Outcome; Female; Humans; Indazoles; Male; Middle Aged; Neoplasm Recurrence, Local; Pyrimidines; Stomach; Stomach Neoplasms; Sulfonamides; Treatment Outcome	2019
Paclitaxel and Pazopanib in Ovarian Cancer. JAMA oncology, 2018, 09-01, Volume: 4, Issue:9 Topics: Female; Humans; Indazoles; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Pyrimidines; Sulfonamides	2018
Paclitaxel and Pazopanib in Ovarian Cancer-Reply. JAMA oncology, 2018, 09-01, Volume: 4, Issue:9 Topics: Female; Humans; Indazoles; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Pyrimidines; Sulfonamides	2018
PARP inhibitors and quality of life in ovarian cancer. The Lancet. Oncology, 2018, Volume: 19, Issue:8 Topics: Double-Blind Method; Female; Humans; Indazoles; Neoplasm Recurrence, Local; Ovarian Neoplasms; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors; Quality of Life	2018
Pazopanib in relapsed osteosarcoma patients: report on 15 cases. Acta oncologica (Stockholm, Sweden), 2019, Volume: 58, Issue:1 Topics: Adolescent; Adult; Aged; Angiogenesis Inhibitors; Bone Neoplasms; Child; Female; Humans; Indazoles; Male; Middle Aged; Neoplasm Recurrence, Local; Osteosarcoma; Progression-Free Survival; Pyrimidines; Salvage Therapy; Sulfonamides; Young Adult	2019
Targeting PARP1 in XRCC1-Deficient Sporadic Invasive Breast Cancer or Preinvasive Ductal Carcinoma Cancer research, 2018, 12-15, Volume: 78, Issue:24 Topics: Apoptosis; Breast Neoplasms; Carcinoma, Intraductal, Noninfiltrating; Cell Cycle; Cell Line, Tumor; Chemoprevention; CRISPR-Cas Systems; DNA Breaks, Double-Stranded; DNA Repair; Female; Germ-Line Mutation; HeLa Cells; Humans; Indazoles; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Phthalazines; Piperazines; Piperidines; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerase Inhibitors; Spheroids, Cellular; Synthetic Lethal Mutations; X-ray Repair Cross Complementing Protein 1	2018
Cost-Effectiveness of Niraparib and Olaparib as Maintenance Therapy for Patients with Platinum-Sensitive Recurrent Ovarian Cancer. Journal of managed care & specialty pharmacy, 2018, Volume: 24, Issue:12 Topics: Clinical Decision-Making; Cost-Benefit Analysis; Female; Health Care Costs; Humans; Indazoles; Models, Economic; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Phthalazines; Piperazines; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors; Progression-Free Survival; United States	2018
Budget impact analysis of niraparib and olaparib for maintenance treatment of platinum-sensitive, recurrent ovarian cancer in the US. Journal of medical economics, 2019, Volume: 22, Issue:2 Topics: Antineoplastic Agents; Budgets; Female; Health Expenditures; Humans; Indazoles; Models, Econometric; Neoplasm Recurrence, Local; Ovarian Neoplasms; Phthalazines; Piperazines; Piperidines; Platinum; Poly(ADP-ribose) Polymerase Inhibitors; Progression-Free Survival; Survival Analysis; United States	2019
Response to Pazopanib in Patients With Relapsed Osteosarcoma. Journal of pediatric hematology/oncology, 2020, Volume: 42, Issue:4 Topics: Adult; Bone Neoplasms; Female; Humans; Indazoles; Male; Neoplasm Recurrence, Local; Osteosarcoma; Pyrimidines; Sulfonamides	2020
Pazopanib Confers a Progression-free Survival in a Patient with Ewing's Sarcoma/Primitive Neuroectodermal Tumor of the Lung. Internal medicine (Tokyo, Japan), 2019, May-01, Volume: 58, Issue:9 Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Fatal Outcome; Humans; Indazoles; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neuroectodermal Tumors, Primitive; Pneumonectomy; Progression-Free Survival; Pyrimidines; Sarcoma, Ewing; Sulfonamides; Treatment Outcome	2019
Prevention of tumor progression in Stewart-Treves syndrome with a low dose of pazopanib. The Journal of dermatology, 2019, Volume: 46, Issue:7 Topics: Aged; Amputation Stumps; Amputation, Surgical; Biopsy; Chemoradiotherapy; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Hemangiosarcoma; Humans; Indazoles; Leg; Lymphangiosarcoma; Neoplasm Recurrence, Local; Progression-Free Survival; Protein Kinase Inhibitors; Pyrimidines; Skin; Skin Neoplasms; Sulfonamides	2019
Targeted composite value-based endpoints in platinum-sensitive recurrent ovarian cancer. Gynecologic oncology, 2019, Volume: 152, Issue:3 Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Female; Genes, BRCA1; Genes, BRCA2; Germ-Line Mutation; Humans; Indazoles; Indoles; Maintenance Chemotherapy; Molecular Targeted Therapy; Neoplasm Recurrence, Local; Organoplatinum Compounds; Ovarian Neoplasms; Phthalazines; Piperazines; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors; Precision Medicine; Randomized Controlled Trials as Topic	2019
The combination of gemcitabine and docetaxel arrests a doxorubicin-resistant dedifferentiated liposarcoma in a patient-derived orthotopic xenograft model. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2019, Volume: 117 Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease Models, Animal; Docetaxel; Doxorubicin; Drug Resistance, Neoplasm; Gemcitabine; Heterografts; Humans; Indazoles; Liposarcoma; Male; Mice; Mice, Nude; Neoplasm Recurrence, Local; Pyrimidines; Sulfonamides; Tumor Burden; Xenograft Model Antitumor Assays	2019
PARP inhibitors: pitfalls and promises. The Lancet. Oncology, 2013, Volume: 14, Issue:9 Topics: BRCA1 Protein; BRCA2 Protein; Female; Humans; Indazoles; Male; Mutation; Neoplasm Recurrence, Local; Neoplasms; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors	2013
Uveal metastasis and myasthenia gravis in a patient with recurrent renal cell carcinoma treated with pazopanib. Clinical genitourinary cancer, 2014, Volume: 12, Issue:4 Topics: Adult; Angiogenesis Inhibitors; Carcinoma, Renal Cell; Humans; Indazoles; Kidney Neoplasms; Male; Myasthenia Gravis; Neoplasm Recurrence, Local; Prognosis; Pyrimidines; Receptors, Vascular Endothelial Growth Factor; Sulfonamides; Uveal Neoplasms	2014
Pazopanib for recurrent extraosseous Ewing's sarcoma of the retroperitoneum. International journal of urology : official journal of the Japanese Urological Association, 2014, Volume: 21, Issue:11 Topics: Fatal Outcome; Humans; Indazoles; Male; Middle Aged; Neoplasm Recurrence, Local; Pyrimidines; Retroperitoneal Neoplasms; Sarcoma, Ewing; Sulfonamides	2014
Sunitinib, pazopanib or sorafenib for the treatment of patients with late relapsing metastatic renal cell carcinoma. The Journal of urology, 2015, Volume: 193, Issue:1 Topics: Aged; Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Female; Humans; Indazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Pyrimidines; Pyrroles; Retrospective Studies; Sorafenib; Sulfonamides; Sunitinib	2015
What next? Choosing second-line therapy in progressive renal cell carcinoma. Oncology (Williston Park, N.Y.), 2014, Volume: 28, Issue:9 Topics: Aged; Angiogenesis Inhibitors; Axitinib; Carcinoma, Renal Cell; Female; Humans; Imidazoles; Indazoles; Kidney Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Neoplasm Recurrence, Local; Prognosis; Pyrimidines; Radiography; Spinal Neoplasms; Sulfonamides	2014
Response of refractory Ewing sarcoma to pazopanib. Acta oncologica (Stockholm, Sweden), 2015, Volume: 54, Issue:7 Topics: Angiogenesis Inhibitors; Bone Neoplasms; Female; Humans; Indazoles; Neoplasm Recurrence, Local; Pyrimidines; Salvage Therapy; Sarcoma, Ewing; Sulfonamides; Young Adult	2015
Promising management of pazopanib-induced liver toxicity. Acta oncologica (Stockholm, Sweden), 2015, Volume: 54, Issue:7 Topics: Angiogenesis Inhibitors; Anti-Inflammatory Agents; Chemical and Drug Induced Liver Injury; Female; Humans; Indazoles; Male; Middle Aged; Neoplasm Recurrence, Local; Prednisolone; Pyrimidines; Salvage Therapy; Sarcoma, Synovial; Sulfonamides	2015
Low-dose administration of oral pazopanib for the treatment of recurrent angiosarcoma. Clinical and experimental dermatology, 2015, Volume: 40, Issue:5 Topics: Administration, Oral; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Female; Hemangiosarcoma; Humans; Indazoles; Male; Neoplasm Recurrence, Local; Protein Kinase Inhibitors; Pyrimidines; Skin Neoplasms; Sulfonamides; Treatment Outcome	2015
Nasal tumoral lesion: challenge. Cutaneous metastasis of renal cell carcinoma. The American Journal of dermatopathology, 2015, Volume: 37, Issue:5 Topics: Aged; Angiogenesis Inhibitors; Biomarkers, Tumor; Biopsy; Carcinoma, Renal Cell; Fatal Outcome; Humans; Immunohistochemistry; Indazoles; Kidney Neoplasms; Male; Neoplasm Recurrence, Local; Nose Neoplasms; Pyrimidines; Skin Neoplasms; Sulfonamides; Time Factors; Treatment Outcome	2015
Primary Pleural Synovial Sarcoma Treated with Pazopanib. Internal medicine (Tokyo, Japan), 2015, Volume: 54, Issue:16 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Chest Pain; Doxorubicin; Dyspnea; Fatal Outcome; Female; Humans; Ifosfamide; Indazoles; Neoplasm Recurrence, Local; Pleural Effusion, Malignant; Pleural Neoplasms; Pyrimidines; Sarcoma, Synovial; Sulfonamides	2015
The clinical outcome of pazopanib treatment in Japanese patients with relapsed soft tissue sarcoma: A Japanese Musculoskeletal Oncology Group (JMOG) study. Cancer, 2016, May-01, Volume: 122, Issue:9 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Chemical and Drug Induced Liver Injury; Disease-Free Survival; Female; Fibrosarcoma; Humans; Hypertension; Indazoles; Japan; Leiomyosarcoma; Liposarcoma; Male; Middle Aged; Neoplasm Recurrence, Local; Neurilemmoma; Pneumothorax; Product Surveillance, Postmarketing; Pyrimidines; Retrospective Studies; Sarcoma; Sarcoma, Synovial; Sulfonamides; Survival Analysis; Thrombocytopenia	2016
Case of complete response to everolimus for metastatic renal cell carcinoma. International journal of urology : official journal of the Japanese Urological Association, 2012, Volume: 19, Issue:9 Topics: Abdominal Cavity; Acute Kidney Injury; Axitinib; Carcinoma, Renal Cell; Combined Modality Therapy; Everolimus; Humans; Imidazoles; Immunosuppressive Agents; Indazoles; Interferon-alpha; Kidney Neoplasms; Lymph Node Excision; Lymph Nodes; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Nephrectomy; Protein Kinase Inhibitors; Remission Induction; Sirolimus; Tomography, X-Ray Computed; Withholding Treatment	2012